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Abstract
Aigialomycin D is a fungal natural product possessing kinase inhibition properties. It
is a member of a class of compounds known as the resorcylic acid lactones, a expansive
group containing compounds exhibiting a vast array of biological activities. These include
kinase and Hsp90 inhibition, highly desirable properties in the drug development field.
This research project sought to capitalise on previous work involving the successful total
synthesis of aigialomycin D. By developing the synthetic methodology, analogues of
aigialomycin D could be prepared for biological testing to obtain valuable structure–
activity relationship information. The focus of this thesis involves the successful synthesis
of aigialomycin D diastereomer, 5′,6′-epi,epi-aigialomycin D and the attempted synthesis
of 10′-epi-aigialomycin D, via the synthetic strategy developed previously in combination
with enantiomeric starting material fragments.
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The synthesis of functional group analogues, 6′-oxo-aigialomycin D, 7′,8′-cyclopropyl
aigialomycin D and 5-chloro-agialomycin D were also attempted via derivatisation of
late-stage intermediates in the aigialomycin D synthesis. The thesis herein recounts the
successes and failures in the synthesis of various aigialomycin D analogues.
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Chapter 1
Introduction
1.1 An Introduction to Analogue Synthesis
Drug discovery is a massive field of social and commercial value (with top pharmaceutical
drugs commonly accumulating annual sales in the US$ billions) that encompasses many
disciplines of chemistry and biology. From the initial discovery of a potential drug, it
takes many years and co-operation between multiple disciplines to get a potential drug on
the market. An important part of that process is the drug optimisation stage. The role of
drug optimisation is to take compounds that have exhibited potentially useful biological
activity and turn them into viable drug candidates.
Natural products provide useful inspiration for potential drug candidates, however, it
is uncommon for natural products to be suitable for medicinal use for various reasons,
such as poor pharmacokinetic properties, target selectivity or chemical stability. This is
reflected in a survey of recent market drugs. Very few (6%) of the 1024 drug compounds
introduced between 1981 and 2008 are unmodified natural products, with 27% natural
product derived, and 17% possessing a natural product pharmacophore.∗ 1 This is where
analogue synthesis–based structural activity relationship (SAR) studies can be highly
valuable in the development of potential drug candidates.
The basic concept of analogue synthesis–based SAR studies is to synthesise analogues of
a chosen compound, which can then be subjected to biological testing to investigate the
effect of the chemical modifications. These studies can help provide a more fundamental
understanding of the importance of individual structural features of a compound for its
observed biological activity, and rationalise the importance of certain structural features,
e.g. in affecting the stability of the compound, or increasing nucleophilicity/electrophilic-
ity of a group that binds to the biological target site.
∗A pharmacophore is the combination of steric and electronic features of a compound (or class of
compounds) that interact with a specific biological target to trigger or inhibit its function.
1
Once the general SARs of a compound have been elucidated, analogue synthesis can
be used to search for potential chemical modification that will improve the drug-
like properties of a compound without having an adverse effect on desired biological
properties. Examples of properties that analogue synthesis studies may seek to improve
are:
• Physiological solubility, stability and absorption to maximise the amount of the
drug that reaches the desired target, improving the efficacy of a drug and potentially
reducing adverse effects due to unwanted biological activity.
• The selectivity of a drug for a desired biological target, reducing unwanted side-
effects of a drug.
• The potency of the drug, reducing the quantity required for treatment.
• Structural simplification of a compound, to enable a more efficient synthesis of
a compound, potentially lowering the environmental and financial costs of drug
production.
For these purposes, analogue synthesis–based SAR studies in combination with other
techniques such as computational studies and co-crystallisation of protein-bound drug
candidates, can help provide invaluable understanding of chemical and biological prop-
erties of potential drug candidates. From this, safer, more effective pharmaceutical drugs
can be developed to improve the lives of the people they affect.
1.2 Resorcylic Acid Lactones
1.2.1 A Brief Description and History of Resorcylic Acid Lactones.
Resorcylic acid lactones (RALs) are a class of mycotoxins isolated from various strains
of fungi defined by the presence a β-resorcylic acid ring and a 14-membered lactone
macrocycle with a methyl substituent at the C10′-position (Figure 1.1). The first
2
example of an RAL, radicicol, was isolated from Monocillium nordinii† in 1953.2
Historically, radicicol was a vanguard of RAL research, generating interest due to
potential antibacterial3–5 and cytotoxic6 properties. Also of early historical importance
was zearalenone, isolated from Gibberella zeae in 1962.7 Zearalenone generated interest
as the compound responsible for the toxicity of an agriculturally damaging fungus.
Additionally, the majority of work elucidating the mechanism of the biosynthesis of
RALs has been done on zearalenone, which was shown to be biosynthesised through a
polyketide synthase (PKS) pathway, the details of which are provided in subsection 1.2.2.
3
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Figure 1.1. General structure and numbering of RAL family
While other RALs were isolated (LL-Z1640-1 to LL-Z1640-4 in 1978,8 hypothemycin
in 1980,9 and monocillins I-V in 198710), RALs only garnered limited interest from
the known biological properties of radicicol. It was not until the late 1990’s that RALs
became a significant class of compounds for medicinal research, initiated by the discovery
of radicicol as a potent and selective inhibitor of Hsp90,11,12‡ as well as the discovery
of hypothemycin and L-783277 as kinase inhibitors.13 Interest in RALs was further
bolstered by the discovery of additional compounds displaying interesting biological
activity, such as the aigialomycins in 2002,14 and the pochonins in 2003.15 Further
details of reported RALs (natural and synthetic) and their known biological properties
are given in subsection 1.2.3. Some examples of selected RALs and their targets are
given in Figure 1.2. These examples highlight the potential value of SAR studies, with
minor variations to the general RAL skeletal structure resulting in significant changes to
selectivity and activity.
†M. nordinii is a mycoparasite known to kill pine stem rusts of Cronartium coleosporioides and
Endocronartium harkenssii
‡Hsp90 (heat shock protein 90) is an ATP-dependant molecular chaperone involved in the stabilisation,
activation and degradation of various proteins.
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Figure 1.2. A selection of RALs and relevant bioactivties
1.2.2 The Biosynthesis of Resorcylic Acid Lactones
Research on zearalenone has shown the biosynthesis to go through a polyketide synthase
(PKS) pathway, involving the condensation and subsequent cyclisation of acetyl-CoA§
as shown in Scheme 1.1. The biosynthesis of zearalenone begins with a highly reducing
PKS (hrPKS), a large multi-domain enzyme with various domains used for condensing
and reducing acyl-CoA units to form a reduced hexaketide-thioester chain. This thioester
chain is then transferred to a non-reducing PKS (nrPKS) where further acyl-CoA units are
condensed to form a mixed reduced/unreduced nonaketide. The resorcylate moiety is then
formed through an aldol condensation of the unreduced portion of the chain, followed by
esterification between the reduced chain hydroxyl and thioester functional groups to form
the macrolactone ring and release zearalenone from the enzyme.16–18
§CoA (coenzyme A) functions as a acyl group donor.
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Scheme 1.1. Proposed biosynthesis of zearalenone. Acyl-units carbon atoms are
represented by bold bonds.
It has been proposed the biosynthesis of hypothemycin and radicicol go through a
similar pathway, involving a hrPKS and nrPKS, with structural variations arising from
differing reduction patterns in the hrPKS step and putative post-PKS enzymatic alterations
(e.g. epoxidation, halogenation).19,20 Scheme 1.2 and Scheme 1.3 shows how various
post-PKS enzymes may be employed to afford the rich diversity of compounds in
the RAL family. For example, hypothemycin is proposed to be biosynthesised via
aigialomycin C, from the initial product, 7′,8′-dehydrozearalenol (Scheme 1.2). After
the formation of 7′,8′-dehydrozearalenol through a PKS pathway, the putative post-PSK
enzymatic alterations are selective 4-O-methylation by an O-methyltransferase (OMT),
1′,2′-epoxidation by a flavin-dependent monooxygenase (FMO) and 5′-hydroxylation
of 7′,8′-dehydrozearalenol by a cytochrome P450 (CYP) monooxygenase to afford
aigialomycin C. Then, subsequent 6′-oxidation by an alcohol oxidase (AOX), Z/E
isomerisation of the 7′-alkene by a glutathione S-transferase (GST) and 4′-hydroxylation
by another CYP to afford hypothemycin.19
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Scheme 1.2. Proposed biosynthesis of hypothemycin.19
The biosynthesis of monocillin I and radicicol are thought to go through a similar
pathway, with the exception of a chlorination step by putative fungal flavin-dependant
halogenase to initially form pochonin D in the biosynthesis of radicicol. A putative CYP
epoxidase is responsible for epoxidation of the 7′-alkene to form monocillin I and the
5-chloro equivalent, ponchonin A. The origin of the (5′Z)-alkene is uncertain, as PKSs
almost exclusively provide (E)-alkenes, and the radicicol gene cluster does not possess a
GST, which has been shown to facilitate isomerisation of the alkene in hypothemycin
analogues. A possible origin of the (Z)-alkene of radicicol and monocillin I is a 5′-
hydroxylation catalysed by a CYP followed by a dehydration step (Scheme 1.3).20
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Scheme 1.3. Proposed biosynthesis of monocillin I and radicicol.20
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1.2.3 An Overview of Structure–Activity Relationships Within the
Resorcylic Acid Lactones
Investigations into the biological activity of the RALs have focused on two groups of com-
pounds: the first group includes radicicol, the pochonins, and related compounds, which
have been the focus of considerable research due to their Hsp90 inhibition properties; the
second group includes hypothemycin, LL-Z1640-2, and related compounds, which have
garnered interest due to their selective kinase inhibition properties. Other RALs have been
isolated that display less noteworthy biological activity, but are useful when considering
SARs within the class of compounds.
Resorcyclic Acid Lactones as HSP90 Inhibitors
Hsp90 is a molecular chaperone that plays an important role in many biological processes
relating to the transport, activation, stabilisation and degradation of various proteins. The
important functions of Hsp90 are in the folding of both nascent and denatured proteins,
ensuring they are in an activated or stabilised form, and in preventing aggregation. Hsp90
is present under normal conditions to assist in these tasks. When exposed to cellular
stresses (e.g. infection, inflammation, changes to temperature, or exposure to toxins)
Hsp90 is over-expressed to maximise the amount of functional proteins, which are known
to include various oncogenic proteins, such as Raf, mutant p53, Her221 and telomerase.22
As a result, Hsp90 has the potential to facilitate the proliferation and survival of various
proteins associated with oncological pathways,23,24 making Hsp90 inhibition an attractive
target for cancer therapy.25,26 Preliminary studies also suggest that Hsp90 inhibitors
accumulate more efficiently in tumour cells than normal cells.27 The specific Hsp90
inhibitor used was a geldanamycin analogue, 17-allylamino-17-demethoxygeldanamycin
(17-AAG), currently in phase II clinical trials, which has a similar biological mechanism
to radicicol.28–30
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Studies have shown that, despite the lack of structural similarity between ATP and either
radicicol or geldanamycin, both inhibit Hsp90 by competitive binding to the ATP binding
site of Hsp90.31 Importantly, radicicol has been shown to only bind to the unique L-
shaped binding pocket (Bergerat fold) present in Hsp90,32,33 and consequently does
not compete with ATP binding in other biological processes. Radicicol also binds to
Hsp90 in its lowest energy comformation,34 while geldanamycin compounds must adopt
a higher energy conformaton,35,36 suggesting radicicol or radicicol analogues may be a
good alternative or even improvement on 17-AAG.
Radicicol has been shown to bind to Hsp90 non-covalently, suggesting the structural
features important for biological activity are those which govern the conformation, and
hydrogen bonding of radicicol to the ATP binding site of Hsp90. Two other groups of
naturally occurring RALs, the monocillins (isolated in 1980 from M. nordinii)37 and
the pochonins (isolated in 2003 from Pochonia chlamydosporia var. catenulata strain
P 0297) have also exhibited Hsp90 inhibition properties.15 Both groups of RALs are
highly structurally similar to radicicol, characterised by a trans-enone functionality and a
(10′R)-methyl group. Figure 1.3 highlights the minor structural variations between these
compounds, and their effect on Hsp90 inhibition. Inhibition of human simplex virus 1
(HSV 1) and WNT-5A¶ are also reported, indicating anti-viral properties15 and potential
for hair growth treatment,38 respectively.
¶WNT-5A (Wingless-type mouse mammary tumour virus integration-site family, member 5A) is one of
the glycoproteins secreted by the WNT family, which are intercellular signalling molecules known to play
important roles in development processes, such as cell proliferation.
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R1 = H, R2 = H 0.4 µM − 7.36 µM
HSV 1 Hsp90 WNT-5A
Radicicol:
R1 = Cl 0.2-0.8 µM 20 nM 0.19 µM
Monocillin I:
R1 = H
− 340 µM 1.93 µM
HSV 1 Hsp90 WNT-5A
Pochonin C:
R1 = Cl 6 µM − 13.28 µM
HSV 1 Hsp90 WNT-5A
Pochonin D:
R1 = Cl, R2 = H >50 µM 80 nM −
Pochonin E: 
R1 = Cl, R2 = OH 1.5 µM − −
Pochonin F:
R1 = H, R2 = OH 2 µM − −
Monocillin II:
R1 = H, R2 = H >50 µM >50 µM 7.36 µM
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Figure 1.3. A selection of natural RALs and known inhibition targets IC50. (– indicates
testing of the compound for this activity has not been reported).
Figure 1.3 shows the isolated RALs that have been found to possess HSV 1, Hsp90
and/or WNT-5A inhibition properties. These compounds highlight the effect of various
alterations around the C5′-C8′ portion of the molecule and chlorination at the C5-
position. Similar RALs have also been isolated (monocillin IV, monocillin V, nordinone
and nordinonediol, Figure 1.4), that have no reported biological activity.10,37 In contrast
to the previously mentioned RALs (Figure 1.3), these RALs possess no functionality
from the C3′-C6′ portion of the molecule or chlorination at the C5-position, suggesting
certain functionality is required at those positions for the compound to inhibit the desired
biological targets.
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Figure 1.4. Selected biologically inactive natural RALs.
Natural RALs provide useful SAR information, but are limited in the type and number of
structural features that occur naturally. Analogue synthesis allows for a more extensive
and systematic analysis of SARs, and can provide greater insight into both the importance
of structural features to biological activity, and the nature of their role (e.g. Michael
acceptor, effect on conformation, hydrogen bonding). Detailed SAR studies have been
conducted around the general structure provided in Figure 1.3, and these show the value
of analogue synthesis–based SAR studies.39–41 These studies were done by synthesising
a combination of analogues possessing single or multiple structural variations, then
comparing the results of biological testing. Early SAR studies were done by making
small variations, such as hydrogenating the alkene moieties, and correlating the effect on
Hsp90 inhibition.39 SAR studies also involved variation of the macrocycle size from 12-
to 16-membered, which suggested 13-, 15- and 16-membered macrocycles may retain
activity.40 However, these studies were done with 3′,4′-dihydro-analogues, which are less
active. Later research by Winssinger et al. on more active pochonin D analogues showed
13- or 15-membered macrocycles led to a significant reduction in biological activity.41
This highlights a flaw of SAR studies; alterations at one position may negate or enhance
the effect of alterations at another.
The unpredictability of correlating SARs of varying systems was further highlighted
by additional results reported by Winssinger et al.41 It was found that the 5-dechloro-
pochonin D analogue (monocillin II) showed a similar EC50 value as pochonin D, while,
in combination with the modification of the 10′-methyl to a ethyl group, chlorination
at the C5-position led to a five-fold increase in affinity. However, in combination
with methylation at the C6′-position, chlorination was found to lower the affinity to
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Hsp90. Other results reported by Winssinger et al. suggested that a hydroxyl at the C6′-
position, and replacement of the C2′-carbonyl with an oxime increases the potency of the
compound. Further evidence was also provided for the importance of the enone system,
with 3′,4′-dihydro analogues all exhibiting decreased affinity to Hsp90. Two promising
analogues that have been developed by these SAR studies are shown in Figure 1.5.
O
OOH
HO
N
O
OOH
HO
O
HO
Cl
O
ON
OH
WNT-5A: IC50 = 1.89 µM,
TC50 = >100 µM
Hsp90: IC50 = 20 nM
µ
Figure 1.5. Selected analogues and biological activities from SAR studies by
Winssinger et al.(left) and Shinonaga et al.(right).
Work by Shinonaga et al. further supports the importance of the enone system for
biological activity and stability, showing analogues lacking a sp2-hybridised centre at
the C3′-position exhibited lower biological activity and lower stability under acidic
conditions. This research also provided SARs relating to the toxicity of analogues, with
results suggesting C5-dechloro analogues are relatively more toxic, and C3′-hydroxyl
and C3′-oxime analogues are relatively less toxic.38 A diagram summarising the SAR
information from the studies outlined previously is provided in Figure 1.6.
O
O
Cl
HO
OH O
O
Essential for inhibition and chemical
stability (dihydro degraded more
easily under acidic conditions).
Not essential for inhibition or
stability. C6'-OH increases
activity and solubility.
Strained system required
for inhibition (i.e. oxirane, 
cyclopropane, or double bond).
14-membered macrocyclic lactone essential for activity.Inhibition lowered when OMe
similar inhibition when OAc.
Similar inhibition when
OMe or OAc.
Effect on inhibition depends
on other functionality.
Increases toxicity when a proton.
sp2-hybridised carbon essential for inhibition of Hsp90.
Oxime analogues showed improved Hsp90 inhibition.
Displays similar inhibition of WNT-5A and significantly lower 
toxicity when (R)-OH, N-OMe and N-OBn. Inactive when (S)-OH.
Figure 1.6. General SAR information of WNT-5A and Hsp90 inhibiting RALs.
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Resorcylic Acid Lactones as Kinase Inhibitors
Kinases are phosphotransferase enzymes responsible for transferring phosphate groups
from a donor molecule (usually ATP) to various substrates. An important class of
these enzymes are the protein kinases; through phosphorylation of protein substrates,
they can play a critical role in various cellular processes, including those associated
with oncological pathways. One such pathway is the mitogen-activated protein kinase
(MAPK) pathway, a three-tiered kinase cascade of signal transducing enzymes which
directly influences processes such as cell survival, proliferation and adaption. The
cascade is comprised of a MAPK, which is activated via phosphorylation by a MAPK
kinase (commonly abbreviated as MAPKK, MKK or MEK), which in turn is activated
via phosphorylation by a MEK kinase (commonly abbreviated as MAPKKK, MKKK
or MEKK), with the entire process up-regulated in response to physical and chemical
stresses.42 It is the MAPKs involved in this cascade that are a major target for RALs
being developed as therapeutic cancer treatment.
The first RALs discovered to possess kinase inhibition properties, hypothemycin and L-
783277, were found to inhibit MEK1, with IC50 values of 15 nM and 4 nM, respectively.13
Other notable RALs exhibiting kinase inhibition are LL-Z1640-2, an inhibitor of TAK1
and ERK2‖ with IC50 values of 8.1 nM and 8.0 nM, respectively,43,44 and radicicol A,
an inhibitor of VEGF-R2/R3, FLT3 and PDGFR-β∗∗ with IC50 values of 26, 66, 110 and
210 nM, respectively.45 These compounds display a high structural similarity, including a
(10′S)-methyl group [compared with the (10′R)-methyl seen in Hsp90 inhibiitng RALs],
a 6′-8′-cis-enone, (4′S,5′S)-diol and 4-O-methyl.
‖TAK1 (transforming growth factor-β activated kinase 1) is a MAPKKK and ERK2 (extracellular signal-
regulated kinase 2) is a MAPK.
∗∗VEGF-R2/R3 (vascular endothelial growth factor receptor 2 and receptor 3), FLT3 (fibromyalgia
syndrome-like tyrosine kinase 3) and PDGFR-β (platelet-derived growth factor receptor-β) are tyrosine
receptor kinases.
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Figure 1.7. Natural RALs which have displayed kinase inhibition properties.
A more comprehensive study found hypothemycin displays significant inhibition†† against
21 out of the 123 kinases tested. 20 of these contained a cysteine (cys) residue, of
these, 18 incorporated a cys residue which corresponds to the cys166 in ERK1/2.46
From co-crystallisation with ERK2, LL-Z1640-2 was shown to convalently bond to the
cys166 residue.43 It was proposed that this covalent bonding would occur thorough a
Michael addition of the cysteine thiol to the C8′-position (Scheme 1.4). This proposed
mechanism would indicate the Michael acceptor properties of the RAL is a crucial factor
in determining kinase inhibition properties.
O O O
S S
CysCys
Cys
S
H
H
Scheme 1.4. Proposed Michael addition of a cysteine thiol to the enone functionality.
Synthesis and subsequent biological testing of a 4-O-desmethyl hypothemycin analogue
showed an increased potency against three human cancer lines (COL829, HT29 and
SKOV3) compared to hypothemycin.47 Two radicicol A analogues have also been
synthesised and tested, a 5-desmethoxy analogue and a 5-chloro analogue; both of
these analogues were found to be less potent compared to radicicol A against all targets
based on IC50 values. The most comprehensive SAR studies on kinase-inhibiting RALs
††Greater than 20% inhibition at 200 nM.
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through analogue synthesis has been done on the development of LL-Z1640 as a anti-
inflammatory drug.48–50
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5-desmethoxy radicicol A 5-chloro radicicol A
Figure 1.8. Reported analogues of hypothemycin and radicicol A.
The Development of E6201: A Potential Anti-Inflammatory Drug
A considerable amount of research has been reported on improving the metabolic stability,
in vivo potency and bioavailability of LL-Z1640-2 as an anti-inflammatory drug through
analogue synthesis. However, as these results were published either during or after the
duration of the research reported in this thesis, a heavily abridged account of the results
will be provided. The first goal of the structure optimisation was to improve the metabolic
stability of the compound, while retaining biological activity;‡‡ this was done by targeting
the double bond of the enone functionality.48 C7′- and C8′-alkene substituted analogues
and C9′-substituted analogues were synthesised. A (9′S)-methyl analogue was found
to possess significantly higher metabolic stability while retaining reasonable biological
activity. Improvement of the in vivo inhibition properties was then attempted by the
substitution of various groups at the C4- and C5-position of the resorcylic ring as well
as the synthesis of C1′-ether and C1′-amide analogues.49 Substitution of the C4-positions
yielded the most positive results, with further research in this direction to improve the
bioavailability of the compound ultimately leading to the development of clinical trial
candidate E6201.50
‡‡Desired biological activity was tested in a TNFα- PLAP reporter assay, and non-specific cytotoxic
activity in a β-actin-PLAP (ACT-PLAP) reporter assay. Stability was measured by the amount (%) of the
compound remaining after 2 h at 37 ◦C in mouse plasma.
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Figure 1.9. The development of E6201 through analogue synthesis.
Miscellaneous Resorcyclic Acid Lactones
Some other RALs have been isolated but possess limited biological activity. Queenslan-
don (Figure 1.10), isolated in 2002 from fungal strain Chrysosporium queenslandicum
IFM51121, has exhibited anti-fungal activity.51
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Figure 1.10. Queenslandon
The caryospomycins (Figure 1.11), isolated in 2007 from fresh-water fungus Caryospora
callicarpa YMF1.01026, have been shown to possess nematicidal activity, with LC50
values around 100 ppm over a 36 hr period.52 No research into the cytotoxic or kinase
inhibition properties of any caryospomycins has been reported.
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Figure 1.11. Caryospomycins
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The most recently isolated group of RALs, the hamigeromycins (Figure 1.12), have shown
limited biological activity. Tests against three human cancer cell lines (KB, MCF-7,
and NCI-H187)∗ at 50 µM and Plasmodium falciparum K1 at 10 µM showed no useful
biological activity. Against Vero cells, only hamigeromcyin A and C displayed growth
inhibition, with respective IC50 values of 42 and 13 µM.53,54
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Figure 1.12. Hamigeromycins
1.3 Aigialomycin D
Aigialomycins (Ams) A-E (1-5) were isolated from mangrove fungus Aigialus parvus
BCC 5311 in 2002 by Isaka et al.14 Of the aigialomycins, only aigialomycin D (AmD)
has been shown to possesses useful biological activity. Biological testing has shown AmD
possesses moderate anti-malarial properties, with an IC50 of 6.6 µM against P. falciparum,
and moderate cyctotoxic properties, with IC50 values of 3.0, 18 and 1.8 µM against KB,
BC-1 and Vero cancer cells, respectively. The observed cytotoxicity may arise from the
kinase inhibition properties of AmD, with IC50 values of 5.7, 5.8 and 14 µM for the
inhibition of kinases CDK1/cyclin B, CDK5/p25 and GSK-3,†respectively.55
∗KB is an oral carcinoma cell line. MCF-7 is a breast cancer cell line. NCI-H187 is a small cell, lung
carcinoma cell line.
†CDK1 (cyclin-dependent kinase 1) and CDK5 are protein kinases involved in the regulation of the
cell cycle. GSK-3 (glycogen synthase kinase-3) are serine/threonine protein kinases that play a key role in
various signalling processes.
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Figure 1.13. Aigialomycins isolated by Isaka et al.
Two additional aigialomycins, F (6) and G (7), were later isolated from the same fungus,
however, they possess 6-membered lactones instead of the 14-membered macrolactones
seen in other RALs, and have no known biological activity.56 A 1′,2′-epoxy analogue
of AmD (8), isolated from Hypomyces subiculosus DSM 11931, also showed no useful
biological activity against human cancer cell lines (COLO829, HT29 and SKOV3).‡ 47
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Figure 1.14. Aigialomycins F and G, and natural epoxy-AmD analogue 8.
Limited SAR studies have previously been done on AmD. Winssinger et al. published
the synthesis of ten AmD analogues (Figure 1.15), mostly focusing on the 5′,6′-diol
portion of AmD. These analogues included deoxy-, methyl- and benzyl-analgoues as
well as a 8′-methoxy-6′-alkene analogue. Second generation 1′,2′-dihydro analogues of
the previous analogues were also prepared. Tests for kinase inhibition properties against
CDK1/cyclin B, CDK5/p25, GSK-3 and PfGSK3 showed no activity for any of the tested
analogues.55
‡COLO829 is a melonoma cell line, and HT29 is a colon cancer cell line; both express mutant B-raf
gene products. SKOV3 is an ovarian carcinoma cell line that expresses the wild-type B-raf gene product.
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Figure 1.15. AmD analogues synthesised by Winssinger et al.
The syntheses of 6′-epi-AmD 9 and 4-methyl AmD 10 have also been reported, however
no biological testing was reported.57,58
O
OOH
HO
OH
OH
O
OOH
MeO
OH
OH
6'-epi-AmD (9) 6'-epi-methyl-AmD (10)
Figure 1.16. 6′-epi-AmD (9) and 6′-epi-4-methyl AmD (10).
1.3.1 Previous Published Syntheses of Aigialomycin D
The first reported synthesis of AmD was published in 2004 by Danishefsky et al.
(Scheme 1.5).59 The synthesis began with 2-deoxy-D-ribose to provide the correct
stereochemistry of the diol moeity, which was transformed to aldehyde 11. A Barbier
reaction of this aldehyde with propargyl bromide (12) and zinc dust, afforded a terminal
alkyne. Then carboxylation with n-butyllithium and carbon dioxide, followed by a
Mitsunobu reaction with (R)-4-penten-2-ol (13) gave the main body of the macrocycle.
After protecting the alkyne as cobalt complex 14, the macrocycle was formed with a
ring-closing metathesis (RCM) reaction catalysed by Grubbs’ second generation catalyst.
Deprotection of the alkyne followed by a Diels-Alder reaction with cyclic diene 15 gave
the resorcylate moiety. Martin’s sulfurane conditions were then used to give the 1′-alkene
through dehydration of the C2′-hydroxyl. Finally, global deprotection afforded AmD in a
total of 18 linear steps and overall yield of 8%.
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Scheme 1.5. a) Danishefsky’s synthetic strategy for AmD. b) The key alkyne protected
as a cobalt complex.
The next synthesis of AmD was reported in 2006 by Pan et al. (Scheme 1.6).60 Sharpless
asymmetric epoxidation followed by a stereoselective ring-opening were used to provide
the diol stereochemistry. Kocienski’s modified Julia reaction was used to couple sulfone
16 with benzylic aldehyde 17, giving the desired (1′E)-alkene. Another Kocienski
modified Julia reaction with chiral sulfone 18, derived from commercially available
(S)-butane-1,3-diol, was used to provide the final part of the molecule and the (7′E)-
alkene. Carboxylation of aromatic bromide 19 with n-butyllithium and carbon dioxide
and subsequent Yamaguchi macrolactonisation were then used to afford protected AmD.
Global deprotection then provided AmD in 18 steps and an overall yield of 2.5%.
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Scheme 1.6. Pan’s synthetic strategy for AmD
Another synthesis of AmD was published in 2006 by Winssinger et al. (Scheme 1.7).55
First, a Mitsunobu reaction was used to couple orsellinic acid 20 with (R)-4-penten-2-
ol (13) to afford the resorcylate portion and provide the C10′ stereocentre. Selenide
21 was then formed by deprotonation of the orsellinate and subsequent reaction with
diphenyldiselenide. Bromide 22 was formed by Sharpless asymmetric epoxidation
followed by a stereoselective ring-opening, and subsequently coupled with selenide 21.
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A RCM with Grubbs’ second generation catalyst followed by oxidative elimination of
the selenide with hydrogen peroxide provided the (7′E)- and (1′E)-alkenes, respectively.
Importantly, it was found that if the RCM was done after the oxidation and elimination
of the selenide, a significant amount of an undesired six-membered ring was formed
by a competing RCM reaction. Global deprotection then yielded AmD in 10 steps
and an overall yield of 21%. The Winssinger synthesis was also adapted as solid
supported synthesis, replacing the selenide with a thiophenol-based Merrifield resin.
This methodology was used to synthesise the AmD analogues shown in Figure 1.15 by
employing various bromide precursors in place of 22.
OH
OO
O
HO
O
O
Mitsunobu reaction
10'
8'
20
13
O
OO
O
Se
Ph
Br
O
O
O
O
RCM1'
2'
7'
Deprotonation
& coupling
21
22
8'
Scheme 1.7. Winssinger’s synthetic strategy for AmD
The fourth synthesis of AmD was published in 2007 by Chen et al. (Scheme 1.8).61 D-
Erythronolactone (23) was used to synthesise Weinreb amide 24 with the desired diol
stereochemistry. A Mitsunobu reaction with the protected orsellinic acid 25 and (R)-
4-penten-2-ol (13) was used to form the resorcylate and C10′ stereocentre, which was
subsequently coupled with Weinreb amide 24 using lithium diisopropylamide (LDA).
Then, a RCM reaction with Grubbs’ second generation catalyst, followed by global
deprotection afforded AmD in 11 steps and an overall yield of 19%.
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Scheme 1.8. Chen’s synthetic strategy for AmD
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The fifth synthesis of AmD was published in 2008 by Montgomery et al. (Scheme 1.9).57
As seen in previous syntheses, a Mitsunobu reaction was used to form the resorcylate
portion and provide the C10′ stereocentre. The odobenzoic acid 26 and (R)-4-pentyn-2-ol
(27) were coupled to form a resorcylate iodide with a terminal alkyne. A Suzuki coupling
was then used to couple the iodide and the boronic acid 28 (prepared from a commercially
available chiral alcohol), providing the desired (1′E)-alkene. The 6′-OTBS group was
then oxidised to form aldehyde 29 and the macrocycle (30) was formed by cyclisation
with Ni(COD)2
§ and IMes.HCl. This reaction yielded a 1:1 mixture of diastereomers that
afforded AmD and 6′-epi-AmD upon global deprotection in 8 steps and an overall yield
of 7%.
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Scheme 1.9. Montgomery’s synthetic strategy for AmD
Synthesis of 6′-epi-AmD (9) from an attempted synthesis of AmD was reported in 2008
by Jennings and Bajwa (Scheme 1.10).58 Commercially available chiral pool precursors
were used to prepare the C5′ and C10′ stereocentre containing fragments, aldehyde 31
and alkyne 32. Coupling of aldehyde 31 and alkyne 32 favoured formation of the
C6′-epi hydroxyl (1:2, natural:C6′-epi), therefore, to enrich the ratio of the desired
stereochemistry, the C6′-hydroxyl was oxidised to a ketone, then reduced with Red-
Al¶ and protected as an isopropylidene acetal to afford 33 as an inseparable mixture
of diastereomers (6:1, natural:C6′-epi). Alcohol 33 was then coupled with substituted
styrene 34. An RCM reaction was then attempted using Grubbs’ second generation
§Ni(COD)2 = Bis(cyclooctadiene)nickel(0)¶Red-Al = sodium bis(2-methoxyethoxy)aluminum hydride
21
catalyst, however, this reaction provided 84% of an undesired six-membered ring product
and only 13% of the desired macrocycle. Interestingly, the macrocycle product of
the RCM was a single diastereomer, the C6′-epimer. 2-Methyl-6′-epi-AmD (35) was
synthesised employing the same methodology, by starting with the 2-methoxy-styrene
36.
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O34
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Scheme 1.10. Jennings’ and Bajwa’s synthetic strategy for 6′-epi-AmD (9) and
2-methyl-AmD (35).
Another synthesis of AmD was reported in late 2009 by Barrett et al. (Scheme 1.11).62
In this synthesis, the entire molecular skeleton was constructed as linear chain, which
was subsequently aromatised and cyclised to form AmD in a similar manner to the
biosynthetic PKS pathway for synthesising RALs. This was achieved by synthesising
dioxinone ester 37 from dioxinone 38, which would become the resorcylate moiety, and
acid choride 39 was derived from chiral pool precursor acetonide 40, which would become
the diol portion of AmD. These two fragments were coupled to form fragment 41, that
contained the desired diol stereochemistry and (1′E)-alkene. Then, upon refluxing in
toluene, the dioxinone moiety rearranged to form a ketene, which was trapped in situ
with (S)-4-penten-2-ol, and aromatised in situ with cesium acetate followed by acetic
acid to provided the resorcylate moiety and C10′ stereocentre containing diene 42. A
RCM reaction with Grubbs’ second generation catalyst, followed by global deprotection
afforded AmD (4) in 11 steps and an overall yield of 15%.
22
O O
O
Cl
O
O
O
O
O
OOHOH
O
OO
OOH
HO
O
O
7'
8'
6
31
10'
2'
1'
1'
6
8'
7'
OHOO
O
1 3
CO2Allyl
O
OO
O
+
O
O
OOHOO
O
1
6 1'3
CO2Allyl
1) morpholine, Pd(PPh3)4
2) PhMe, D, (S)-4-penten-2-ol;
    CsOAc, AcOH
AmD (4)
RCM & deprotection
38 37
40 39
41
42
Scheme 1.11. Barrett’s synthetic strategy for AmD
1.3.2 The VUW Synthesis of Aigialomycin D
The Victoria University of Wellington (VUW) synthesis of AmD was developed by a
previous member of this research group, PhD student Dr Lynton Baird. This route
involved the coupling of three portions (Scheme 1.12). Thioacetate 43 was prepared
in eight steps from D-ribose to incorporate the desired diol stereochemistry. This was
coupled to resorcylic bromoester 44, prepared in three steps from methyl acetoacetate.
A Mitsunobu reaction was then employed to couple (R)-4-penten-2-ol (13) with acid
45 to provide the C10′ stereochemistry as seen in previous syntheses. Like previous
syntheses, a RCM reaction was also used to close the macrocycle. However, a salient
feature of this synthesis is the masking of the 1′-alkene as a sulfone until the end of the
synthesis, when it is revealed with a Ramberg-Ba¨cklund reaction, thus avoiding any by-
products associated with attempting a RCM reaction on a triene system. As with previous
syntheses, a base orthogonal protection scheme was also used, employing acid-sensitive
protecting groups.63,64
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Scheme 1.12. The VUW synthetic strategy for AmD
For Dr Baird’s synthesis, methyl orsellinate (46) was synthesised in a one-pot condensa-
tion/cyclisation reaction of methyl acetoacetate (47) as previously reported by Chiarello
et al.65 The reaction was found to be very unreliable and heavily dependant on the quality
of the reagents used; occasionally only starting material was recovered and the most
successful result provided a modest 40% yield. Methyl orsellinate was then acetylated
(acetic anhydride, triethylamine in dichloromethane, 98%) followed by bromination with
N-bromosuccinimide (NBS) and benzoyl peroxide in carbon tetrachloride (71%) to yield
aromatic bromide 44. Acetate protecting groups are essential for this reaction, as the
electron withdrawing properties of acetyl groups deactivate the ring towards electrophilic
aromatic substitution. When more electron donating groups, such as methyl ethers were
used, bromine substitution at the C5-position was found to be the major process.
OMe
OOH
HO
OMe
OOAc
AcO
Br
46 44
70%OMe
OO
NaH, THF, 0 ºC,
then n-BuLi,
-78 ºC to reflux
then 10% HCl, 
     pH 1, ∆
i) Ac2O, NEt3,
   CH2Cl2
ii) NBS, [PhC(O)O]2,
    CCl4, ∆
40%
47
Scheme 1.13. Synthesis of bromide 44 from methyl orsellinate
Iodide 48 was prepared in three steps in an overall yield of 46% from D-ribose using a
known literature method.66 A Vasella reaction was then used to provide aldehyde 49.67
Upon completion, the reaction mixture was filtered through silica to remove the zinc salts
from the reaction, and the Wittig reagent added to the reaction mixture to afford the α,β-
unsaturated ester 50 (74%, 1:4.7 E:Z). The mixture of (E)- and (Z)-alkenes obtained from
the Wittig reaction was not an issue as the next step was the reduction of this alkene.
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Scheme 1.14. Synthesis of α,β-unsaturated ester 50 from D-ribose.
The selective reduction of the α,β-unsaturated ester was attempted with NaBH4 at 0
◦C,
but yielded only starting material. Addition of transition metal catalyst CuCl was found to
greatly improve the reduction, with desired saturated ester 51 obtained in excellent yield
(96%) with no by-products detected. By comparison, it was found that when CuCl2 was
employed as the transition metal catalyst, various by-products were isolated, including
fully saturated ester 52 (5%), dehydro ester 53 (10%) and lactone 54 (10%). Thioacetate
43 was then synthesised effortlessly in three steps from ester 51 in an overall yield of 89%.
This was achieved by reduction of the ester to an alcohol with lithium aluminium hydride
(97%), followed by mesylation of the alcohol with methanesulfonyl (mesyl) chloride
(97%), and finally conversion of the mesylate to the thioacetate with potassium thioacetate
(95%).
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Scheme 1.15. Synthesis of thioacetate 43 from α,β-unsaturated ester 50 and attempted
selective reduction with CuCl2.
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Bromide 44 and thioacetate 43 were then coupled by an in situ deprotection with
potassium carbonate in methanol to yield coupled product 55 (86%). Attempted
saponification of this methyl ester showed decarboxylation at the C1-position occurred
when the C2-hydroxyl was not protected. Therefore, coupled product 55 was protected
with MOM-chloride, by deprotonation with sodium hydride in dimethylformamide
(DMF) followed by addition of MOM-chloride (74%). Saponification of the protected
MOM-product with potassium hydroxide in 1:1 methanol/water at reflux for 12 hours
proceeded with ease to afford carboxylic acid 45 in 98% yield. Acid 45 was then coupled
with chiral alcohol (R)-4-penten-2-ol in a Mitsunobu reaction (94%).68 The thioether
56 was then oxidised to sulfone 57 with meta-chloroperoxybenzoic acid (m-CPBA) in
dichloromethane at 0 ◦C (84%).
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Scheme 1.16. Synthesis of sulfone 57 from the coupling of bromide 44 with thioacetate
43.
Next, a RCM reaction with Grubbs’ second generation catalyst (58) provided the
macrocycle 59 (86%) containing the desired (7′E)-alkene. Finally, a Ramberg-Ba¨cklund
reaction was used to reveal the 1′-alkene providing only the desired (E)-isomer (60).
The Meyers-modification of the Ramberg-Ba¨cklund reaction was used, which is a one-
pot in situ α-halogentation and α-deprotonation, leading to the spontaneous chelotropic
exclusion of sulfur dioxide to form the alkene.69 The original Ramberg-Ba¨cklund reaction
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required an α-halo-sulfone starting material.70 Global deprotection then afforded AmD
(4) in 16 steps (longest linear sequence) and an overall yield of 9%.
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Scheme 1.17. Synthesis of AmD (4) from sulfone 57.
Two analogues of AmD were also successfully synthesised, tetrahydro-AmD (61) and
2,4-deoxy-AmD (62).64 Tetrahydro-AmD (61) was synthesised by palladium catalysed
hydrogenation of the 1′- and 7′-alkenes of protected AmD 60, followed by global
deprotection in 89% yield over two steps. 2,4-Deoxy AmD (62) was synthesised by
starting with methyl 2-methyl benzoate (63) instead of methyl orsellinate, to which the
previously employed methodology was applied. All subsequent reactions were found to
proceed similarly to those in the natural AmD synthesis.
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Scheme 1.18. Synthesis of tetrahydro-AmD 61 and 2,4-deoxy-AmD 62.
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Unsuccessful attempts were made to synthesise two other AmD analogues: 10′-epi-AmD
(64) and 5-chloro-AmD (65).64
O
OH
OH
OH
HO
O
10'-epi-AmD (64)
O
OH
OH
OH
HO
O
5-chloro AmD (65)
Cl
Figure 1.17. AmD analogues, 10′-epi-AmD (64) and 5-chloro-AmD (65).
The alternative stereochemistry at the C10′-position was obtained by using a Steglich
esterification to couple acid 45 and (R)-4-penten-2-ol, which does not lead to inversion
of the stereocentre as a Mitsunobu reaction does. This reaction was found to be low
yielding (32%), which ultimately resulted in insufficient material to finish the synthesis.
The oxidation of the obtained thioether 66 to sulfone 67 and the RCM reaction were found
to give similar yields to the natural product synthesis. The Ramberg-Ba¨cklund reaction
of 68 was also tried, however attempts to purify the compound by silica flash column
chromatography failed.
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Scheme 1.19. Unsuccessful synthesis of epi-AmD 64.
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Chlorination of protected AmD (60) was attempted with calcium hypochlorite in 10%
aqueous acetic acid, a method successfully employed in previous radicicol syntheses.71,72
Only starting material was recovered from this reaction.
O
O
MOMO
MOMO
O
O
60
O
O
MOMO
MOMO
O
O
Cl
Ca(OCl)2,
10% AcOH(aq)
X
65
Scheme 1.20. Unsuccessful synthesis of 5-chloro-AmD 65.
1.4 Research Objectives
The aim of the research described herein was to synthesise specific AmD analogues in
order to conduct SAR studies of AmD. The syntheses of the chosen analogues would
involve variation of the methodology previously developed by Dr Baird. Potential
analogues were chosen based upon chemical availability and potential SAR importance,
as indicated from previous studies on related compounds. Two types of analogues were
proposed: diastereomers of the three chiral centres of AmD, and analogues with varied
chemical functionality. AmD represents an interesting section of the RAL family, as it
is the only member with known kinase inhibition properties that does not possess the
enone functionality seen in other RALs. Hence, SAR studies on these AmD analogues
should provide important information relating to the biological activity mechanism and
selectivity of AmD-like compounds compared with more thoroughly investigated RAL
compounds. Identification of unique mechanisms or selectivity would be valuable for
the evaluation of AmD related compounds as potential medicinal compounds. Results
of SAR studies from the compounds synthesised in this research should also serve to
expand the knowledge base of SAR information for RALs, a class of compounds valuable
for medicinal research arising from exhibited potent and selective Hsp90 and kinase
inhibition properties.
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Diastereomeric analogues 10′-epi-AmD (64) and 5′,6′-epi-AmD (69) were selected in
order to elucidate the importance of the chiral centres and consequent conformation for
the biological activity of AmD.‖
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OOH
HO
OH
OH
10'-epi-AmD (64)
O
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HO
OH
OH
5',6'-epi,epi-AmD (69)
Figure 1.18. Proposed diastereomeric analogues of AmD.
Previous research has shown a Michael addition at the C8′-position by a cys thiol is one
of the main mechanisms of kinase inhibition displayed by numerous RALs. Thus, 6′-oxo-
AmD 70 was also proposed to improve the Michael acceptor properties at the C8′ position
of AmD. The reactivity of the 7′-alkene could also be investigated with 7′,8′-cyclopropyl-
AmD 71.
O
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HO
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OH
6'-Oxo-AmD 70
O
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HO
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OH
7',8'-Cyclopropyl-AmD 71
Figure 1.19. Proposed functional group analogues of AmD.
Once synthesised, these compounds would be submitted for biological assays. Cell
biology experiments and chemical genetics would be used to evaluate the biological
properties.
A secondary aim of this research was to optimise the synthetic methodology developed by
Dr Baird to help facilitate the synthesis of the proposed analogues and future analogues
of AmD. This involved a shortened synthesis of the thioacetate fragment (43) and various
other modifications. The low yielding and unreliable synthesis of methyl orsellinate was
also a focus of optimisation research.
‖These two analogues are enantiomers of one another and diastereomers of AmD.
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1.4.1 Proposed Synthetic Methodology
An optimised synthesis of iodide 48 was proposed (Scheme 1.21). The use of acetyl
chloride instead of conc. hydrochloric acid for the protection of D-ribose could potentially
increase the yield of the product. Methyl esterification and isopropylidene formation are
both reversible acid catalysed reactions, with excess water causing a reversion to starting
material. Hence, it was proposed that the use of acetyl chloride to form anhydrous
hydrochloric acid in situ would reduce the amount of water, and drive the equilibrium
of the reaction towards the desired product. A one-step iodination at the C5-position
of D-ribose was also proposed (Scheme 1.21), instead of the two-step reaction sequence
used previously that involved conversion of the hydroxyl to a tosylate and subsequent
displacement with nucleophilic iodine (Scheme 1.14).
OMeO
O
O
I
OHO
HO
OH
OH
i) MeOH, acetone, AcCl
ii) I2, PPh3, imidazole
    2:1 toluene/CH3CN
48D-Ribose
Scheme 1.21. Proposed optimised synthesis of iodide 48.
A synthesis of 5′,6′-epi,epi-AmD (69) from D-ribose was proposed (Scheme 1.22). The
α,β-unsaturated ester 72 possessing the desired diol stereochemistry could be prepared
by a Wittig reaction with known aldehyde 73, which can be prepared in three steps
from D-ribose.73 The previously developed synthetic methodology could then be used
to afford the epi,epi-AmD 69. The periodate cleavage/Wittig reaction sequence could
also potentially be done as a two-step, one-pot reaction (analogous to methodology
employed in the synthesis of natural AmD) by employing polymer-bound74 or silica-
bound75 periodate. The polymer- or silica-bound periodate could be filtered off upon
completion of the oxidative cleavage, and the Wittig reagent added to the reaction mixture,
avoiding the isolation of the unstable and volatile aldehyde (73). The use of polymer- or
silica-bound periodate also removes the need for water as a co-solvent, which is usually
necessary due to the low solubility of sodium periodate in organic solvents, such as
dichloromethane.
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Scheme 1.22. Proposed synthesis of 5′,6′-epi,epi-AmD (69).
Previous work by Dr Baird suggested a non-inversive esterification reaction, instead of
the Mitsunobu reaction, would be the only synthetic alteration required to synthesise
10′-epi-AmD (64). However, the low yields observed from the DCC-mediated Steglich
esterification suggested an alternate esterification method would be required. Steglich es-
terification using EDCI,76 esterification with HBTU77 and Yamaguchi esterification78 are
all non-inversive esterification methods which would provide the desired stereochemistry.
Alternatively, Mitsunobu reaction conditions with (S)-4-penten-2-ol could also provide
the desired stereochemistry (Scheme 1.23).
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(S)-4-penten-2-ol,
PPh3, DIAD, THF
60 66
10'-epi-AmD (64)
(R)-4-penten-2-ol,
and Steglich conditions
or HBTU coupling
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Scheme 1.23. Proposed synthesis of 10′-epi-AmD (64).
It was proposed that 6′-oxo-AmD (70) could be prepared through selective oxidation of
AmD itself (Scheme 1.24). Literature precedent exists for the selective oxidation of allylic
alcohols, such as the C6′-hydroxyl of AmD, with manganese dioxide79 or DDQ.80–82
DDQ would be the preferred oxidant due to the potential of manganese dioxide to cause
1,2-diol cleavage.83–86
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Scheme 1.24. Proposed synthesis of 6′-oxo-AmD 70.
The cyclopropanation of alkene 59 using Simmons-Smith conditions87 would be at-
tempted to ultimately afford cyclopropyl-AmD 71 (Scheme 1.25). The proposed
stereochemistry of the cyclopropyl group is based on literature precedence, showing
that addition occurs on the same face as the allylic ether due to coordination of the
reactive zinc species with the oxygen of the ether.88 The rationale for performing the
cyclopropanation on the pre-Ramberg–Ba¨cklund product is to avoid the potential side-
reaction of cyclopropanation at the 1′-alkene. However, the allylic alcohol system of
AmD may sufficiently direct the desired Simmons-Smith cyclopropanation at the C7′-
alkene, allowing the reaction to be done on AmD.
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Cyclopropyl-AmD 71
59
Scheme 1.25. Proposed synthesis of 7′,8′-cyclopropyl-AmD 71.
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Chapter 2
Synthesis of Methyl Orsellinate
Due to the inefficiency and inconsistency of current methyl orsellinate (46) syntheses,
attempts were made to optimise its formation. The reaction was first attempted using
the one-pot method employed by Dr Baird,63,64 where the triketo-ester (74) is formed by
addition of methyl acetoacetate (75) to a solution of sodium hydride in THF stirring at
0 ◦C, followed by addition of n-butyllithium at −78 ◦C and stirring of the solution, first
for 12 hours at room temperature, then a further 24 hours at reflux. The triketo-ester is
then cyclised by acidifying the solution to pH 1 with 10% hydrochloric acid and stirring
at room temperature for 12 hours. The results of this reaction were found to be very
inconsistent, with yields of 0–50% recorded.
OMe
O OOO
OH
HO
OMe
O10% HCl, 
pH 1, 12 h
46
74
OMe
OO
NaH, THF,
0 ºC, 1 h
0~50% 
over two steps
Then
n-BuLi, -78 ºC to rt,
12 h followed by 
24 h at reflux
75
Scheme 2.1. Two-step, one-pot synthesis of the methyl orsellinate from methyl
acetoacetate
2.1 Investigation of Previous Methyl Orsellinate
Syntheses
The original synthesis of methyl orsellinate reported by Harris and Harris89 involved a
two-step reaction sequence, whereby the triketo-ester was isolated before the cyclisation
step. The triketo-ester was synthesised via a Claisen condensation of mono- and di-
anionic methyl acetoacetate (75). This was first achieved by addition of a solution
of the mono-anion in THF (formed by deprotonation of 75 with sodium hydride) to a
solution of the di-anion in THF (formed by deprotonation of 75 with LDA), affording
the triketo-ester in 31% yield.90 A one-pot variant was later developed by Chiarello et
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al.65 that involved deprotonation of 75 with sodium hydride to form the mono-anion, and
successive deprotonation with a strong lithium base (e.g. LDA or n-butyl lithium) to form
the di-anion. It was proposed that only a catalytic amount of the mono-anion would be
required (which could be achieved by using less than one equivalent of the lithium base)
because a further equivalent would be regenerated by proton transfer of the more acidic
α-proton of the di-anionic triketo-ester to the di-anion of 75 (Scheme 2.2). The di-anion
of 75 could also be deprotonated by the methoxide liberated by the Claisen condensation.
Proton transfer from the resulting methanol to the di-anion of 75 would also lead to the
regeneration of the mono-anion. This one-pot reaction was found to afford the triketoester
in an improved yield of 59%.91,92 Optimisation of the condensation step as part of the one-
pot methyl orsellinate synthesis was attempted by Dr Baird via variation of the solvent
used (THF, diethyl ether and hexanes), the reaction temperature during n-butyllithium
addition (0, −40 or −78 ◦C) and the reaction time (24–40 hours), with no success.64
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Scheme 2.2. Base catalysed condensation of methyl acetoacetate.
Cyclisation of trianionic 74 to methyl orsellinate (46) can be achieved under a variety of
conditions. The first reported cyclisation to methyl orsellinate employed basic conditions,
with methanolic sodium acetate providing 46 in 50% yield. Aqueous potassium hydroxide
was also found to facilitate the cyclisation to methyl orsellinate (46) to a lesser degree,
in a yield of 27%, along with 2,4,6-trihydroxyacetophenone [76 (39%)] and orsellinic
acid [77 (13%)] as shown in Scheme 2.3.93 It has also been noticed that 74 efficiently
cyclises to form methyl orsellinate on activated silica gel (81% yield).92 Optimisation of
the cyclisation led to the use of a pH 9.2 buffer, affording methyl orsellinate in a 67%
yield from methyl acetoacetate.94 Near the completion of this research, it was reported
by another group that cyclisation could be achieved efficiently with caesium carbonate in
methanol followed by acidic work-up, in a yield of 87% from 74.95 The aforementioned
cyclisation methods were all conducted on the isolated triketo-ester, while the focus of this
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research project was to develop a one-pot method similar to that reported by Chiarello et
al.,65 and previously used by Dr Baird.
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Scheme 2.3. Cyclisation of triketo methyl ester to methyl orsellinate.93
Our investigation of the methyl orsellinate synthesis began with the one-pot synthesis
developed by Chiarello et al. Monitoring the reaction with TLC showed one spot (RF =
0.40) before acidification. After acidification, three spots were visible by TLC. RF values
of 0.55 (corresponding to methyl acetoacetate), 0.45 (corresponding to methyl orsellinate)
and a baseline spot were observed, of which was presumed to be orsellinic acid (77) or a
related carboxylic acid compound(s). 1H NMR spectroscopy of the product mixture also
suggested the presence of a significant amount of methyl acetoacetate. It is unknown
whether degradation to methyl acetoacetate through a retro-Claisen-like reaction was
occurring or if the first TLC of the reaction mixture was inaccurate due to the effect
of components in the reaction mixture on the retention factors of methyl acetoacetate.
From this initial analysis, the cyclisation step was identified as the possible reason for
the low and inconsistent yields obtained previously. As studies focusing on isolating the
triketo-ester and cyclising it in a separate step were concurrently undertaken by a summer
student in the research group with limited success,∗ the separate condensation/cyclisation
approach was not further studied in this research.
∗Dunn, E.; Ting, S.; Harvey, J., Unpublished results, 2010.
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2.2 Optimisation Studies on the in situ Cyclisation of the
Triketo-ester
To assess potential alternative cyclisation methods, 74 was formed as outlined previously
(section 2.1) and the reaction mixture was then divided into five aliquots. Each sample was
subjected to different cyclisation conditions overnight at room temperature, then checked
by TLC before being isolated and examined by 1H NMR spectroscopy (Table 2.1).
Table 2.1. Cyclisation of triketo-ester 74
Entry Conditionsa TLC spotsb 1H NMR resultsb Yieldc
SM MO BL SM MO BP (%)
1
Acidified to pH 1 with
10% HCl X X X X X X 20
2
Buffered at pH 2 with
HCl/KCl trace X trace minor X trace 40
3
Acidified to pH 3 with
AcOH trace X trace X X trace 60
4
Stirred with silica gel
(100 mg/mL) X X x X trace x 10
5
Buffered at pH 9.2
with NaHCO3/Na2CO3
x x X x x X 0
aAll samples stirred at rt. overnight
bSM = starting material, MO = methyl orsellinate, BL = baseline, BP = by-products
cIsolated yield of methyl orsellinate
The initial cyclisation method of Chiarello et al.65 was included as a control (entry 1,
Table 2.1). Milder acidic conditions seemed to reduce the amount of TLC baseline
products (entries 2 and 3, Table 2.1), with acidification to pH 3 (acetic acid) giving the
highest yield of methyl orsellinate (60%, entry 3, Table 2.1). Inspired by the cyclisation
on silica gel reported by Harris et al.92 silica gel was added to an aliquot of the reaction
mixture. While the TLC of this reaction showed promising results, with no baseline spots,
the 1H NMR spectrum of the crude product showed only traces of methyl orsellinate, and
this was confirmed by the low isolated yield of 10% (entry 4, Table 2.1). Cyclisation in
an aqueous solution buffered at pH 9.2 (sodium bicarbonate/sodium carbonate) was then
attempted to explore whether this method could be employed to cyclise the triketo-ester in
its tri-anionic form, as it would likely exist in the reaction mixture. No methyl orsellinate
or methyl acetoacetate were observed by TLC or 1H NMR, and no methyl orsellinate was
isolated (entry 5, Table 2.1).
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Hydrolysis of a methyl ester to a carboxylic acid can occur under harsh acidic or basic
conditions in the presence of water, therefore, the exclusion of water could reduce
carboxylic acid related by-products. Two anhydrous cyclisation methods were attempted:
i) quenching the reaction with methanol followed by acidification to pH 1.5 with acetyl
chloride, and ii) quenching the reaction with methanol followed by acidification to pH
5 with glacial acetic acid. The results of both these methods were promising, with
yields of 40% and 66%, respectively. The latter result is especially interesting, as it
suggests cyclisation of the triketo-ester to methyl orsellinate is possible under milder
acidic conditions than previously reported. Unfortunately, cyclisation with acetic acid
in methanol was also found to be inconsistent, with yields of methyl orsellinate from
subsequent reactions in the range of 20–60%. Residual acetic acid, leading to the
formation of a concentrated acidic solution upon evaporation of the solvent and resulting
degradation of the products, was considered as a possible explanation for the inconsistent
yields. Neutralisation of the acid with saturated sodium bicarbonate was trialled as a
possible solution with little success, providing yields of 15–20%. Due to time constraints
and with adequate amounts of methyl orsellinate obtained, no further optimisation was
undertaken.
2.3 Synthesis of Resorcylic Bromoester 44
The synthesis of resorcylic bromoester 44 was achieved as previously reported by Harvey
et al.63 After the synthesis of methyl orsellinate (46) as discussed in the previous section,
the phenolic groups of 46 were acetylated with acetic anhydride and triethylamine.
Benzylic bromination was then accomplish by refluxing the acetylated methyl orsellinate
in carbon tetrachloride with NBS and a catalytic amount of a radical initiator (benzoyl
peroxide) to afford rescorcylic bromide 44 in a yield of 79% over two steps (Scheme 2.4).
OMe
OOH
HO
OMe
OOAc
AcO
Br
46 44
79%OMe
OO
NaH, THF, 0 ºC,
then n-BuLi,
-78 ºC to reflux
then MeOH,, 
AcOH, pH 5
i) Ac2O, NEt3,
   CH2Cl2
ii) NBS, [PhC(O)O]2,
    CCl4, reflux
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Scheme 2.4. Synthesis of resorcylic bromoester 44.
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Chapter 3
Synthesis of Aigialomycin D
The majority of target analogues within this research project could be prepared through
divergent modifications of the AmD synthesis developed at VUW,63,64 or through
derivatisation of AmD itself. Thus, repetition of the AmD synthesis was required and
provided a logical first step en route to the synthesis of AmD analogues. To facilitate
the synthesis of these and any future analogues, various optimisations were made to
the methodology, aimed to improve the yield and reproducibility, reduce the number of
reaction steps and/or simplifying experimental procedures.
3.1 Synthesis of the Thioacetate 43.
A simplified, and potentially higher yielding, seven-step synthesis of thioacetate 43 from
D-ribose via iodide 48 was proposed (Scheme 3.2).
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I
OHO
HO
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OH
D-Ribose 48
 i) MeOH, acetone, AcCl
ii) I2, PPh3, imidazole
    2:1 toluene/CH3CN
AcS
O O
43
Scheme 3.1. Synthesis of the thioacetate fragment from D-ribose.
First, D-ribose was protected as methyl 2,3-O-isopropylidene-β-D-ribofuranoside (78)
using acid-catalysed acetal formation in a solution of 1:1 acetone/methanol. Instead of
employing concentrated hydrochloric acid as used previously, which is a ∼35% aqueous
solution, acetyl chloride was used to form anhydrous hydrochloric acid in situ, minimising
the amount of water in the reaction. It was hoped that this would drive the equilibrium
towards the desired product (Scheme 3.2). An improved yield of 80% of the protected
sugar 78 was obtained in sufficient purity for immediate use, with none of the α-anomer
observed. The C5-hydroxyl was then iodinated via a known literature method of refluxing
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the substrate in a solution of toluene/acetonitrile (2:1) with triphenylphosphine, imidazole
and iodine,96 affording iodide 48 in 80% yield and an overall yield of 64% over two steps
from D-ribose.
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AcCl, ∆
48
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O
O
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80%80%
O
HO
OH
HO OH
78
I2, PPh3, imidazole
2:1 toluene/CH3CN, ∆
Scheme 3.2. Synthesis of iodo-sugar 48 and proposed equilibrium mechanism
Thioacetate 43 was then prepared from iodide 48 as reported by Harvey et al.63 A Vasella
reaction was conducted with zinc powder and acetic acid in refluxing methanol, to form
aldehyde 49. To avoid isolation of the unstable aldehyde, the reaction mixture was
filtered through a silica plug to remove zinc salts, then the stabilised Wittig reagent
[methyl (triphenylphosphoranylidene)acetate] added directly to the cooled eluent. This
reaction was found to give a similar ratio of E:Z isomers (1:5.1) and yield (75%) of
α,β-unsaturated ester 50 as previously reported. The selective reduction of the α,β-
unsaturated ester also proceeded as previously reported, however, it was found that freshly
purified copper (I) chloride was required for the reaction to go to completion.∗ Ester 51
was then reduced to the corresponding alcohol (lithium aluminium hydride in diethyl
ether at –10 ◦C) followed by conversion to its mesylate ( mesyl chloride, DMAP and
triethylamine in dichloromethane). Nucleophilic displacement of the mesylate group
was achieved through reaction with potassium thioacetate in DMF to afford thioacetate
43 in an overall yield of 38% in seven steps from D-ribose (Scheme 3.3). This is an
improvement over the eight-step route that gave an overall yield of 28% from D-ribose
previously reported by Harvey et al.63
∗Copper (I) chloride is a pale grey powder that can turn light green over the course of weeks, even when
stored under argon, possibly due to exposure to adventitious moisture.
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Scheme 3.3. Synthesis of thioacetate 43 from iodo-sugar 48
3.2 Synthesis of AmD from Thioacetate 43 and Resor-
cylic Bromoester 44.
Slight variations were made to the route from thioacetate 43 to AmD (4) reported by Dr.
Baird.63,64 The coupling of resocylic bromide 44 to deacetylated thioacetate 43 proceeded
without issue. However, significant difficulties were then encountered when attempting
to protect the hydroxyl groups of product 55 as methoxymethyl ethers.
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74%
Scheme 3.4. Coupling of thioacetate 43 and resorcylic bromoester 44
The original method involved deprotonation of the phenolic groups with sodium hydride
in DMF at 0 ◦C, followed by addition of MOM-chloride, to afforded the desired product
(75%).63 However, when this method was repeated in the current work, lower yields
were obtained (50–60%), with the major by-product being mono-protected product 79
(Scheme 3.5).
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Scheme 3.5. Attempted MOM-protection of 55
The difficulty in protecting the C2-hydroxyl is likely due to hydrogen bonding between
the C2-hydroxyl and the neighbouring ester carbonyl, forming a stable six-membered
system. Evidence for this hydrogen bonding is seen in the 1H NMR spectrum, where the
C2-hydroxyl proton is seen as a sharp singlet at 11.68 ppm (see Appendix for relevant
spectra).† Another interesting consequence of the proposed hydrogen bonding of this
hydroxyl is the apparent effect on polarity, with protection of the C2-hydroxyl as a
methoxymethyl ether leading to a decrease in Rf on silica TLC, implying an increase
in polarity.‡ This is counter intuitive as protection of hydroxyl groups is usually expected
to decrease the polarity of the compound. The stability of the C2-hydroxyl system would
appear to negate the necessity for protection of this group;§ however it was known that
the unprotected hydroxyl facilitates decarboxylation of the carboxylic acid functionality
under saponification conditions,97–99 through the proposed mechanism of Scheme 3.6.64
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Scheme 3.6. Proposed mechanism for the decarboxylation of the resorcylic acid moiety.
In an attempt to obtain the fully protected product 80, MOM-protection of the mono-
MOM product 79 was attempted utilising the same method. Unfortunately a similar
ratio of di-MOM:mono-MOM products was obtained. The reaction was also attempted
†Hydroxyl protons are commonly observed as broad peaks or not observed at all in 1H NMR spectra
due to the exchangeability of these protons. The shape of the peak can be characteristic of the exchange
rate of the proton.
‡Mono-MOM 79 had an Rf of 0.50, compared with 0.34 for di-MOM 80 and 0.27 for the unprotected
55 in 2:1 hexanes/ethyl acetate.
§Hydroxyl groups are usually protected to decrease the polarity of the compound, making it easier to
isolate and purify, and to minimise unwanted side-reactions associated with their reactivity.
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with tetrabutylammonium iodide (TBAI) as an additive, which was expected to form the
more reactive MOM-iodide in situ. Unfortunately, TBAI had no observable effect on the
reaction. The possible degradation of the MOM-chloride reagent was then considered.
In the presence of water, MOM-chloride could be hydrolysed to MOM-OH, which could
then react with another equivalent of MOM-chloride to form the MOM-O-MOM dimer
(Scheme 3.7). Degradation of MOM-chloride to formaldehyde and methanol would also
likely occur. The presence of these by-products would not only decrease the concentration
of the MOM-chloride in the reaction mixture, but their formation would also release
hydrochloric acid, which could have an adverse effect on the reaction. It was hypothesised
that hydrochloric acid could either quench the reaction or deprotect the product in situ.
Due to time constraints and the unavailability of alternative batches of MOM-chloride,
neutralisation with DMAP or triethylamine was attempted as a possible solution, however
neither was found to have an observable effect on the reaction. Excess sodium hydride
was not used due to its potential to deprotonate the benzylic protons, leading to additional
by-product formation.
O O
Cl H2O O OH O O O+
MOM-Cl
-HCl -HCl
MOM-Cl
Scheme 3.7. The proposed degradation of MOM-chloride
Purification of the MOM-chloride was also attempted by washing with saturated calcium
carbonate followed by fractional distillation. While 1H NMR spectroscopy of the reagent
suggested that purification led to a significant increase in the ratio of the degraded reagent
to MOM-chloride, use of the purified MOM-chloride afforded di-MOM 80 in ∼80%
yields (Scheme 3.8). Interestingly, the only by-product isolated was starting material;
no mono-MOM product was observed.
Next, ester 80 was saponified to carboxylic acid 45 by refluxing with potassium hydroxide
in a solution of 2:1 methanol/water. Originally, the acid was isolated after neutralisation
of the basic reaction mixture with 10% acetic acid. However the acetic acid was difficult
to separate from the organic layer, leading to degradation of the compound, most likely
due to deprotection of the acid sensitive methoxymethyl ether and isopropropylidene
protecting groups. Removal of the acetic acid by evaporation led to loss of product, again
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probably due to deprotection of the compound 45. When excess washing with water was
used, acid 45 was extracted into the aqueous layer. To get around this problem, use of
a weak inorganic acid was proposed in place of acetic acid because it could easily be
removed with an aqueous wash. Use of a 10% aqueous solution of potassium hydrogen
sulfate was found to successfully avoid acid-catalysed degradation, and gave acid 45 in
excellent yield (Scheme 3.8).
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Scheme 3.8. MOM-protection followed by saponification of ester 55
A Mitsunobu reaction was then used to couple acid 45 and (R)-4-penten-2-ol (13) to give
diene 56. The optimal order of reagent addition was found to be addition of the alcohol
to a solution of triphenylphosphine and DIAD in THF at 0 ◦C. This mixture was stirred
for 30 minutes to allow formation of the activated alcohol. Acid 45 was then added as
a solution in THF. It was found that the reaction took a few days to reach completion,
however, quenching the reaction after 24 hours avoided degradation. Unfortunately, the
remaining acidic starting material was inseparable from the by-products of the reaction,
preventing its recovery.
Oxidation of thioether 56 with m-CPBA in dichloromethane then afforded sulfone 57.
Next, a microwave-assisted RCM, catalysed by Grubbs’ second generation catalyst (58),
was utilised to form the macrocycle 59. This reaction proceeded smoothly, however,
removal of the catalyst residue proved difficult. The catalyst residue was found to streak
on a silica column in the various solvent systems used, contaminating all product eluted
from the column. Stirring with activated carbon was investigated to determine whether the
catalyst residue would be preferentially absorbed onto the carbon. However, significant
product loss was observed and traces of the catalyst residue were still present. Ultimately,
repeated flash column chromatography proved the most efficient method of removing the
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catalyst by-product with minimal loss of product. Additionally, possible remaining traces
of the catalyst did not seem to interfere with subsequent reactions.
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Scheme 3.9. Synthesis of sulfone 59 from acid 45
The second alkene was subsequently revealed using a Ramberg-Ba¨cklund reaction. Using
the Meyers-modified Ramberg-Ba¨cklund reaction,69 carbon tetrachloride was added
dropwise to a stirred solution of the sulfone 59 and excess potassium hydroxide (20
eq.) in 5:2 tert-butanol/dichloromethane, yielding protected AmD 60. The desired (1′E)-
alkene was the exclusive product observed from this reaction. Global acidic deprotection
was then achieved by stirring the protected AmD in a solution of 1:1 v/v methanol/1 M
hydrochloric acid at room temperature for 3 days to afford AmD (4) in an overall yield of
6% in 15 steps (longest linear sequence) from D-ribose.
O
O
MOMO
MOMO
O
O
10% HCl/MeOH
rt., 3 days
67%
60
AmD (4)
KOH, t-BuOH, 
CH2Cl2, then
CCl4, 35 ºC
86%
59
Scheme 3.10. Synthesis of AmD (4) from sulfone 59
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Chapter 4
Synthesis of 5′,6′-epi,epi-Aigialomycin D
To avoid the arduous task of developing entirely new synthetic methodology, it was
proposed that the epi,epi-AmD analogue could be synthesised via the natural AmD
synthetic route through use of a starting material possessing the desired 5′6′-diol
stereochemistry. We envisaged the required diol stereochemistry could be obtained from
D-ribose using the pseudo-symmetry of this chiral pool reagent. Forming the alkene
functionality at the C1-terminus of the molecule, and the aldehyde at the C4-terminus
would reverse the carbon chain terminus relative to the AmD synthesis. The resultant
aldehyde 73 thereby may converge with the previously employed synthetic methodology
(Scheme 4.1). Through this route previously tested synthetic methodology could be used,
and the use of the vastly more expensive L-ribose in a route mirroring that of the natural
AmD could be avoided.
O
OH
HO
OH
D-Ribose
O
O O
HO O
OOH
HO
OH
OH73 69
Scheme 4.1. Proposed synthetic strategy towards 5′,6′-epi,epi-AmD.
4.1 Synthesis of Thioacetate 81
The synthetic route to thioacetate 81, with the 5′,6′-epi,epi stereochemistry relative to
AmD, was proposed to proceed via aldehyde 73, followed by application of the previously
employed methods. Aldehyde 73 could be prepared by a known literature method
involving 2,3-O-isopropylidene protection of D-ribose, followed by a Wittig reaction at
the anomeric centre to form the alkene functionality of 83 and a diol cleavage at the
C4,C5-diol to form aldehyde 73.73
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Scheme 4.2. Proposed synthesis of thioacetate 81.
4.1.1 Development and Optimisation of the Wittig Reaction Route to
Alkene 83
First, D-ribose was protected to give 2,3-O-isopropylidene-ribose (82, 84%) by use of
a catalytic amount of concentrated sulfuric acid and acetone (Scheme 4.3). In solution,
the protected sugar 82 would form an equilibrium between the hemiacetal species and
an open-chain aldehyde species. It is with this open-chain aldehyde species that the
following Wittig reaction was expected to occur. The Wittig reaction was attempted
by addition of a solution of the protected sugar 82 in THF to a solution of the ylide,
pre-formed by stirring methyl triphenylphosphonium bromide (2.3 eq.) in a solution of
potassium tert-butoxide (2.8 eq.) in THF.73 No reaction was observed after 24 hours, with
only starting material and a triphenylphosphine by-product isolated from the reaction.
Variations in the reaction conditions were then explored.
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Scheme 4.3. Attempted synthesis of alkene 83.
Extending the reaction time to three days at room temperature followed by two days at
reflux still gave only starting material (entry 2, Table 4.1). To account for the possible
poor quality of the potassium tert-butoxide, either an excess of (entry 3, Table 4.1)
or freshly prepared potassium tert-butoxide (entry 4, Table 4.1) were also used, but
50
only starting material was isolated in either trial. Addition of 18-crown-6 (to improve
the reactivity of potassium tert-butoxide) also had no success (entry 5, Table 4.1).
Quenching of the Wittig reagent before addition of the sugar was considered as a potential
cause of the lack of reactivity. To test this hypothesis, the order of reagent addition
was altered. Instead of pre-forming the ylide, potassium tert-butoxide was added to
a solution of protected sugar 82 and methyl triphenylphosphonium bromide in THF.
Again, no reaction was observed (entry 6, Table 4.1). The use of alternative bases to
pre-form the ylide was then investigated. n-Butyllithium and LDA were tried with no
success (entry 7-9, Table 4.1); however, when the ylide was pre-formed with potassium
bis(trimethylsilyl)amide (KHMDS), a trace amount of trimethylsilyl (TMS)-protected
alkene 84 was obtained (entry 10, Table 4.1).
Table 4.1. Attempted Wittig reaction of 2,3-O-isopropylidene-ribose (82)
Entry Conditionsa Product
1 Literature method73 (step 2, Scheme 4.2) Only SM observed
2
Left stirring for 3 days at rt. and 2 days at
reflux Only SM observed
3 Excess t-BuOK used (4.0 eq.) Only SM observed
4
Excess freshly prepared t-BuOK used
(4.0 eq.) Only SM observed
5
Wittig pre-formed with t-BuOK (3.0 eq.)
and 18-crown-6 (0.1 eq.) Only SM observed
6
t-BuOK added to a solution of the
protected sugar and CH3PPH3Br
Only SM observed
7
Wittig reagent pre-formed with n-BuLi at
−78 ◦C Only SM observed
8
Wittig reagent pre-formed with LDA (3.0
eq.) at −78 ◦C Only SM observed
9
Wittig reagent pre-formed with LDA (4.0
eq.) at −78 ◦C Only SM observed
10 Wittig pre-formed with KHMDS (2.4 eq.)
Traces of TMS-protected
alkene 84
aLiterature method 73 (step 2, Scheme 4.2) used with variations as indicated
CH3PPh3Br,
KHMDS, THF
then sat. NH4Cl
84
O
OH
HO
O
O
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O O
82
Scheme 4.4. Synthesis of TMS-protected alkene 84.
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The slight reactivity with KHMDS could be due to its mild silylating properties, the
chemical properties of KHMDS, or a combination of both. First, the role of the observed
silylation was investigated. TMS-chloride was employed as a more efficient silylating
agent based upon the hypothesis that if the silylation is a crucial element of the reaction,
increasing the efficiency of the silylation may increase the efficiency of the conversion
to the alkene. To maximise the efficiency of silylation, the sugar 82 was pre-treated
with TMS-chloride and imidazole to provide silylation conditions, before addition to
a solution of the ylide reagent, pre-formed with KHMDS. These conditions provided
almost complete conversion to the alkene (entry 1, Table 4.2, Scheme 4.5), a considerable
improvement over the use of only KHMDS. Unfortunately, the starting material was
inseparable from the product, and three different TMS protected products∗ were also
isolated from the reaction.† The majority of the TMS groups were found to be removed in
situ during the mildly acidic liquid–liquid extraction with a saturated ammonium chloride
solution.
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KHMDS, TMSCl
THF then 
sat. NH4Cl
O
OH
HO
O
O
OR1
R2O
O O
82
O
OH
HO
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82 R1 = TMS, R2 = TMS
R1 = TMS, R2 = H
R1 = H, R2 = TMS 
R1 = H, R2 = H (83)
+
Scheme 4.5. Synthesis of alkene 83 and various TMS protected alkenes.
To test whether the improved result was simply due to the imidazole, a solution of sugar
82 and imidazole was added to a solution of the Wittig reagent deprotonated with n-
butyllithium, a base which can form ylide H2C−PPh3 but does not possess silylating
properties. This reaction afforded only starting material (entry 2, Table 4.2). This
indicated that silylation was a key component in the success of the reaction, therefore, tert-
butyldimethylsilyl chloride (TBDMS-Cl) was tested as an alternative, less labile silylating
agent. Addition of a solution of the silylating agent (TBDMS-Cl), imidazole and sugar 82
to a solution of the ylide pre-formed with n-butyllithium showed no observable Wittig
∗These products appeared to be the 4-O-TMS, 5-O-TMS and 4,5-di-O-TMS protected alkenes based on
1H NMR spectroscopy of the combined products. They were not purified and characterised.
†An estimated yield based on the 1H NMR spectrum was ∼70% of the desired alkene (85) and >1% of
each TMS-protected product.
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reaction, instead only 5-O-TBDMS and 1,5-di-O-TBDMS protected starting material
were isolated (entry 3, Table 4.2). To determine whether the successful reaction (entry
1, Table 4.2) was due to the unique properties of TMS, or if KHMDS was also necessary
for the reaction, a solution of TMS-chloride, imidazole and sugar 82 was added to a
solution of the Wittig reagent formed with n-butyllithium (entry 4, Table 4.2). No product
was isolated from this reaction, suggesting KHMDS is necessary for the desired reaction
to occur.
Table 4.2. Optimisation of the Wittig reaction of 2,3-O-isopropylidene-ribose (82)
Entry Conditions Products
1
Solution of TMSCl (1.2 eq.), imid. (1.5
eq.), sugar added to ylide pre-formed with
KHMDS (3.2 eq.). Scheme 4.5
∼70% alkenea and three TMS-
alkene products
2
Solution of imid. and sugar added to ylide
pre-formed with n-BuLi. Only SM observed
3
Solution of TBDMSCl (1.2 eq.), imid.
(1.5 eq.) and sugar added to ylide pre-
formed with n-BuLi (3.0 eq..)
5-O-TBDMS and 1,5-O-
TBDMS protected SM.
4
Solution of TMSCl (1.2 eq.), imid. (1.5
eq.) and sugar added to ylide pre-formed
with n-BuLi (3.0 eq.)
Only SM observed.
aAs an inseparable mixture of 0.2:1 SM/product.
To simplify the synthetic methodology, imidazole was omitted from the reaction mixture,
and harsher deprotection conditions (addition of 10% hydrochloric acid at 0 ◦C) were
trialled to ensure complete removal of the TMS groups. These conditions were initially
found to be very encouraging, affording only the desired alkene 83 in 87% yield (entry 1,
Table 4.3), but the hydrochloric acid deprotection proved inconsistent. Repeated attempts
of the reaction required longer times stirring in an acidic solution to completely remove
the TMS groups. Prolonged stirring with 10% hydrochloric acid led to lower yields,
likely due to the ensuing loss of the isopropylidene group and consequently loss of this
material in the aqueous work-up (entries 2 & 3, Table 4.3). As significant isopropylidene
deprotection appeared to occur before complete TMS deprotection was achieved in 10%
hydrochloric acid, a milder acid was investigated. For this purpose a 20% aqueous
solution of potassium hydrogen sulfate was employed (entry 4, Table 4.3). This proved
successful, as the desired product could be consistently isolated in ca. 80% yield after one
hour stirring at 0 ◦C (Scheme 4.6).
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Table 4.3. Optimisation of the in situ TMS-deprotection
Entry Wittig reaction in situ deprotection Yield (%)a
conditions Reagents Conditions
1 step 1, Scheme 4.6 10% HCl 0 ◦C, 15 min. 87
2 step 1, Scheme 4.6 10% HCl 0 ◦C, 45 min. 18
3 step 1, Scheme 4.6 10% HCl 0 ◦C, 30 min. 45
4 step 1, Scheme 4.6 20% KHSO4 0
◦C, 1 h. 80
aIsolated yield of alkene 83.
CH3PPh3Br,TMS-Cl
KHMDS, THF,
-78 ºC to rt
overnight
20% KHSO4
1 h
80%
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Scheme 4.6. Synthesis of alkene 83.
These results suggest KHMDS is necessary for an effective Wittig reaction in this complex
system, moreover TMS-chloride improves the yield of the reaction, but the role of each
of these reagent is uncertain. The reason the reaction occurs with KHMDS but not
with n-butyllithium, could be due to the steric or electronic nature of each base. A
previous report stated the reaction could be conducted with potassium tert-butoxide,73
which suggests a sterically hindered potassium base may be required for the reaction to
occur. The effect of TMS-chloride may be due to it trapping the aldehyde species in the
open-chain form, which can then react with the Wittig reagent. More research would
be required to determine the role of each reagent in the reaction, which was not a focus
of this study. Instead, with the alkene in hand, focus shifted to the diol cleavage/Wittig
reaction sequence to form α,β-unsaturated ester 72.
4.1.2 Optimisation of the Diol Cleavage/Wittig Sequence
It was proposed that α,β-unsaturated ester 72 could be formed by 1,2-diol cleavage
of 83, followed by reaction of aldehyde 73 with the stabilised Wittig reagent, methyl
(triphenylphosphoranylidene)acetate (Scheme 4.7).
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Scheme 4.7. Proposed synthesis of α,β-unsaturated ester 72.
In order to develop a one-pot variant of this reaction sequence analogous to the natural
AmD synthesis, the use of polymer- or silica-bound periodate was proposed as this
would allow the reagent to be filtered off upon completion of the diol cleavage reaction
and prior to the Wittig reaction. The reaction with polymer-bound periodate‡ in both
dichloromethane (entry 1, Table 4.4) and methanol (entry 2, Table 4.4) was attempted with
limited success. This is possibly due to the low loading of the periodate on the polymer,
resulting in insufficient periodate reagent, or the reactivity of the reagent. However,
the concentration of the polymer-bound reagent could not be accurately determined,
so the reason is unknown. Silica-bound periodate§ was then tried as an alternative,
with only slightly greater success (entry 3, Table 4.4). Again, the concentration of the
reagent loaded onto the silica was unknown and potentially insufficient, so an alternative
approach was tried. Instead of using silica-bound periodate, NaIO4 was employed and
silica gel added after the reaction was deemed complete by TLC in order to remove the
periodate by-products. This was followed by addition of the Wittig reagent providing
the α,β-unsaturated ester 72 in 83% yield (entry 4, Table 4.4). This method allowed for
accurate measurement of the periodate reagent, and no adverse affect was observed in the
subsequent Wittig reaction from any residual periodate.
Table 4.4. Optimisation of the diol cleavage/Wittig reaction of diol 83
Entry Reagents Solvent Conditions Yield (%)a
1 Polymer-bound periodate CH2Cl2 overnight, rt. <1%
2 Polymer-bound periodate MeOH overnight, rt. 20%
3 Silica-bound periodate MeOH overnight, rt. 35%
4 NaIO4
b MeOH 3 h, rt. 83%
aIsolated yield of α,β-unsaturated ester 72.
bNaIO4 by-products were removed by stirring with silica gel followed by filtration.
‡Polymer-bound periodate was prepared by the procedure by Harrison and Hodge.74
§Silica-bound periodate was prepared by the procedure by Zhong and Shing.75
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Scheme 4.8. Synthesis of α,β-unsaturated ester 72.
The Wittig reaction was found to give the same E/Z ratio of isomers (1:5.1) as the
natural synthesis. 1H NMR spectroscopic data of the α,β-unsaturated ester isomers (E)-
and (Z)-72, possessing the inverse diol stereochemistry matched those of the previously
synthesised α,β-unsaturated ester isomers, (E)- and (Z)-50 (see section 3.1).
4.2 Synthesis of 5′,6′-epi,epi-Aigialomycin D
It was proposed that 5′,6′-epi,epi-AmD (69) could be synthesised from α,β-unsaturated
ester 72 using the methodology employed in the natural AmD (4) synthesis.
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69
Scheme 4.9. Proposed synthesis of 5′,6′-epi,epi-AmD (69).
Thus, selective reduction of the α,β-unsaturated ester 72 with copper (I) chloride and
sodium borohydride in methanol at −78 ◦C afforded 86 in 88% yield. Ester 86 was
then reduced to the corresponding alcohol 87 (lithium aluminium hydride in diethyl ether
at −10 ◦C) followed by conversion to its mesylate, which was displaced by potassium
thioacetate to form the thioacetate 81 in an overall yield of 32% in seven steps from D-
ribose (Scheme 4.10).
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Scheme 4.10. Synthesis of thioacetate 81 from α,β-unsaturated ester 72.
Thioacetate 81 was coupled with resorcylic bromoester 44 to afford coupled thioether
88. The phenolic hydroxyls were then protected as MOM-ethers by deprotonation of
the phenolic groups with sodium hydride at 0 ◦C followed by the addition of MOM-
chloride, and the ester then hydrolysed to carboxylic acid 89 by refluxing with a solution
of potassium hydroxide in water/methanol (Scheme 4.11).
 i) NaH, DMF,
     0 ºC, then
     MOM-Cl
     0 ºC to rt,
ii) KOH, 2:1             
   MeOH/H2O
    ∆, 2 days
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+
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Scheme 4.11. Synthesis of acid 89 from thioacetate 81 and resorcylic bromoester 44.
A Mitsunobu reaction was then used to couple acid 89 and chiral alcohol 13 to afford diene
90. The thioether was then oxidised to the corresponding sulfone with m-CPBA, followed
by a microwave–assisted RCM catalysed with Grubbs’ second generation catalyst (58) to
form the macrocycle 91. Like the natural AmD synthesis, both the RCM and Ramberg-
Ba¨cklund reaction afforded only the desired (E)-alkenes (92). The product was then
deprotected by stirring in a solution of 1:1 v/v methanol/1M hydrochloric acid for 2 days.
Deprotection provided a 90% yield of epi,epi-AmD (69) and an unknown isomer (19:1
69:isomer) in an overall yield of 3% in 15 steps (longest linear sequence) from D-ribose.
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Scheme 4.12. Synthesis of 5′,6′-epi,epi-AmD 69 from acid 89.
The final reactions were found to be much lower yielding than the corresponding reactions
in the natural AmD synthesis (Scheme 4.12). It is unknown whether this is due to the
altered 5′,6′-diol stereochemistry. The low yields of the RCM (67%) and Ramberg-
Ba¨cklund reaction (64%) imply that the altered diol functionality has an impact on the
conformation of the 15- and 14-membered macrocycles formed in these reactions, making
the desired products less favoured. However, due to the structural distance of the diol
from the carboxylic acid and thioether functionality, inversion of the diol stereochemistry
would not be expected to greatly affect the Mitsunobu and thioether oxidation reactions.
Simple model building (Figure 4.1) supports this hypothesis, suggesting that the low
yields of these two reactions within the 5′,6′-epi,epi series were unlikely to be caused
by the altered stereochemistry. As the desired product 69 had been obtained, no further
investigation into the origin of the low yields or optimisation of the synthesis were
undertaken.
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Figure 4.1. Molecular models of acid 45 (top) and the 5′,6′-epi,epi-acid 89 (bottom).
Separation of the isomers was achieved with reverse phase HPLC (C18, 80% methanol/wa-
ter, Rt = 8 min), subsequent NMR characterisation of the compound confirmed the major
product was the desired 5′,6′-epi,epi-AmD (69). In comparison to the 1H NMR spectrum
of AmD (4), the spectrum of the epi,epi-AmD analogue 69 displayed two significantly
shifted peaks; unsurprisingly the peaks associated with the C5′-proton and C6′-proton.
The peak assigned as the C6′-proton was shifted from 4.35 ppm (in the 1H NMR spectrum
of 4) to 4.66 ppm (in the 1H NMR of 69), and the peak assigned as the C5′-proton was
shifted from 3.63 ppm (in the 1H NMR spectrum of 4) to 4.24 (in the 1H NMR spectrum
of 69). There is also significant differences in the observed coupling constants relative to
AmD, these are discussed further in section 6.1.
Unfortunately, only a small amount of the unknown isomer, contaminated with 5′,6′-
epi,epi-AmD in a ratio of 2:1, was isolated by HPLC, which was insufficient to fully
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characterise the compound. From high-resolution mass spectroscopy (HRMS), it was
confirmed the unknown isomer had the same mass as AmD. The 1H NMR spectrum
suggested the compound was the (7′Z)-isomer (93) based on the following evidence: i)
the peak assigned as the C8′-proton in the (7′E)-isomer spectrum (at 6.08 ppm) is a minor
peak in this spectrum. However, a peak which integrates for two protons is observed at
5.60 ppm, which is possibly the C7′- and C8′-protons of the (7′Z)-alkene; ii) the peak
assigned as the C6′-proton is shifted from 4.66 ppm in the (7′E)-isomer spectrum to 5.05
ppm in the unknown; iii) as the remainder of the peaks in this spectrum correlate well with
those expected for the (7′E)-isomer spectrum, the variation between the two compounds
obtained from the deprotection reaction is probably at the 7′,8′-positions.
+
69
Figure 4.2. 1H NMR spectrum of 2:1 mixture of putative isomer 93 and epi,epi-AmD 69
(500 MHz, acetone-d6).
A possible mechanism for the formation of the (7′Z)-isomer involves acid–catalysed
isomerisation (Scheme 4.13). Protonation of the 7′,8′-alkene to form a carbocation would
allow rotation of the C7′-C8′ bond, and subsequent deprotonation would reform the
alkene. It is possible the C6′-alcohol could stabilise the positive charge at the 7′-position.
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The formation of the (Z)-isomer suggests it is more favoured relative to the (E)-isomer
of this system compared with the natural AmD system (see chapter 6 for computational
calculations)
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Scheme 4.13. Proposed acid-catalysed isomerisation of 5′,6′-epi,epi-AmD (69).
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Chapter 5
Synthesis of 10′-epi-Aigialomycin D (64)
The synthetic strategy to obtain 10′-epi-AmD analogue 64 involved a stereo-retentive
esterification of acid 45, an intermediate in the AmD synthesis, with (R)-4-penten-2-ol.
By altering the esterification step to retain the stereochemistry of the alcohol in the
coupling, the desired (R)-ester (66) could be synthesised from the same starting materials
used in the natural AmD synthesis. After this stage, the AmD synthetic methodology
could be employed en route to 10′-epi-AmD (Scheme 5.1).
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Scheme 5.1. Proposed synthesis of 10′-epi-AmD 64.
5.1 Synthesis of Ester 66
Previous research by Dr Baird employed a Steglich esterification with limited success,
therefore, model studies were conducted to optimise the conditions prior to use on the
real system. The model system was the coupling of 2-methylbenzoic acid (2,4-dehydro-
orsellinic acid, 94) and racemic alcohol 4-penten-2-ol. (Scheme 5.2).
OH
O
O
O4-penten-2-ol
coupling reagent
94 95
Scheme 5.2. Esterification model study
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5.1.1 Stereo-Retentive Esterification Model Studies
Stereo-retentive esterification was first done using the methodology employed by Dr Baird
for comparison purposes, whereby racemic 4-penten-2-ol was added to a solution of acid
94 and DMAP (2.0 eq.) in dichloromethane followed by DCC (1.1 eq.), to afford the
ester (95) in 52% yield (entry 1, Table 5.1). EDCI (1.1 eq.) in combination with DMAP
(2.0 eq.) was found to be only slightly more successful, affording ester 95 in 58% yield
(entry 2, Table 5.1). While this yield was only slightly greater, the EDCI method was
favoured due to its easier practical application.∗ Increasing the quantities of the reagents
was found to improve the yield of the reaction, with EDCI (1.5 eq.) in combination with
DMAP (3.0 eq.) gave 73% yield of the desired ester (entry 3, Table 5.1). An alternate
order of reagent addition was also tried, whereby a solution of the acid 94 was stirred with
DMAP (3.0 eq.) and EDCI (1.5 eq.) before addition of 4-penten-2-ol. This was based on
the reaction mechanism, which involves the formation of an activated ester (96), followed
by conversion into a more reactive activated DMAP-amide; after addition of the alcohol,
nucleophilic attack on this species forms the ester (Scheme 5.3). However, this was found
to give a lower yield of the ester (entry 4, Table 5.1).
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Scheme 5.3. Model stereo-retentive esterification system and proposed Steglich
esterification mechanism.
∗The high water solubility of the urea by-product from the EDCI reaction allows it to be easily removed
by aqueous extraction.
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The coupling reagent HBTU was also investigated. HBTU (1.1 eq.), in combination with
DMAP (3.0 eq.), was found to give a modest yield of 95 (57%, entry 5, Table 5.1), while
HBTU and triethylamine yielded only traces of the desired product (entry 6, Table 5.1).
The best result was obtained using HBTU (1.5 eq.), DMAP (3.0 eq.) and triethylamine
(3.0 eq.), affording ester 95 in a 75% yield (entry 7, Table 5.1).
Table 5.1. Esterification model studies.
Entry Reagentsa Yield (%)b
1 DCC (1.1 eq.), DMAP (2.0 eq.) 52%
2 EDCI (1.1 eq.), DMAP (2.0 eq.) 58%
3 EDCI (1.5 eq.), DMAP (3.0 eq.) 73%
4 EDCI (1.5 eq.), DMAP (3.0 eq.), pre-treated acidc 52%
5 HBTU (1.1 eq.), DMAP (3.0 eq.) 57%
6 HBTU (1.5 eq.), NEt3 (3.0 eq.) <1%
7 HBTU (1.5 eq.), DMAP (3.0 eq.), NEt3 (3.0 eq.) 75%
aAll reactions (except 4) were done by addition of the alcohol, followed by the coupling reagent, to a
solution of acid 94 and DMAP and/or NEt3 in CH2Cl2 at 0
◦C and left to warm to rt. overnight.
bIsolated yield of ester 95
cAlcohol added to a solution of acid 94, EDCI and DMAP in CH2Cl2 at 0
◦C and left to warm to rt.
overnight.
5.1.2 Attempted Stereo-retentive Esterification of Acid 45
The preceding model studies suggested two esterification methods that would be more
effective than the DCC and DMAP method previously used by Dr Baird (entries 3 and 6,
Table 5.1). Esterification of acid 45 was first attempted with EDCI and DMAP, but it was
relatively unsuccessful, affording the ester 66 in only 30% yield.
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Scheme 5.4. Steglich esterification of acid 45.
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The esterification was then attempted with HBTU, DMAP and triethylamine, which
afforded none of the desired ester. Interestingly, the only product isolated from this
reaction was a product tentatively characterised as the HBTU adduct 97 (10% yield),
suggesting the activated ester was not susceptible to nucleophilic attack. This is
potentially due to steric influence of the aromatic ring ortho substituents causing the
carboxylic acid carbonyl to be rotated out of the plane of the ring. In this conformation,
the ortho substituents would hinder the approach of nucleophiles to the carbonyl carbon.
Alternatively, it was hypothesised the lack of reactivity could be due to the higher electron
density of the O-substituted benzylic ring creating an electron-rich carbonyl moiety,
which would be less susceptible to nucleophilic attack than the model system. While
speculative, the electron-rich carbonyl moiety would explain the low yields observed
in the Steglich and HBTU-mediated esterification reactions, which rely on nucleophilic
attack at the carbonyl of the activated ester, by the alcohol (Scheme 5.3). Based on this
hypothesis, reactions such as Steglich, HBTU and Yamaguchi esterification (where the
acid behaves as an electrophile) would be disfavoured. However, the Mitsunobu reaction,
which occurs through nucleophilic attack by the acid on an activated alcohol, would be
favoured. With this in mind, it was decided that the most effective route to (R)-ester 66
would likely be through a Mitsunobu esterification of acid 45 with the enantiomeric chiral
alcohol, (S)-4-penten-2-ol (98).
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Scheme 5.5. Attempted HBTU coupling of acid 45 and alcohol 13.
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5.1.3 Stereo-invertive Esterification of Acid 45
The Mitsunobu reaction of (S)-4-penten-2-ol (98) with acid 45 was found to afford the
desired (R)-ester 66 in a good yield (86%, Scheme 5.6). The 1H NMR spectrum of
this compound was very similar to that of the previously synthesised (S)-ester (56), and
in combination with 13C NMR and HRMS, confirmed the desired compound had been
obtained. The result of this reaction supports the previous hypothesis that the electron
density of the acid functionality would favour reactions where the acid behaves as a
nucleophile, such as the Mitsunobu reaction. With the (R)-ester (66) in hand, the synthesis
of 10′-epi-AmD (64) could proceed.
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Scheme 5.6. Mitsunobu esterification of acid 45 with (S)-4-penten-2-ol (98).
5.2 Attempted synthesis of 10′-epi-Aigialomycin D (64)
from Ester 66
Oxidation of the thioether 66 to the corresponding sulfone with m-CPBA, followed by
the microwave-assisted RCM, to afford the macrocycle 68 in a reasonable overall yield
(59%, Scheme 5.7). A Ramberg-Ba¨cklund reaction was then used to reveal the 1′-alkene,
affording the protected epi-AmD (99). As seen in previous syntheses, only the (1′E)-
alkene was observed, however, a relatively low yield was obtained (57%).
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Scheme 5.7. Synthesis of protected 10’-epi-AmD 99 from epi-ester 66.
The protecting groups were then removed by stirring in 1:1 v/v methanol/1 M hy-
drochloric acid at room temperature for two days, providing a 3:2 mixture of two RAL
compounds.† The identities of the two compounds could not be accurately identified from
the 1H NMR of the crude reaction mixture, although, neither compound appeared to be
the desired 10′-epi-AmD. Unfortunately, all attempts to separate the two compounds were
unsuccessful.
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Scheme 5.8. Deprotection of protected 10’-epi-AmD 99.
The difficulty associated with separating the compounds may have been due to the
significantly higher polarity of these compounds relative to AmD (4) and 5′,6′-epi,epi-
AmD (69). This higher polarity was most evident when purification by reverse-phase
HPLC was attempted. In solvent systems from 75% to 95% methanol/water, a retention
time (Rt) of 3 minutes was observed, which equates to the solvent front of the systems;
this is compared with a retention time of 7–8 minutes in 80% methanol/water for AmD
(4) and 5′,6′-epi,epi-AmD (69). As the two compounds could not be separated, full
identification and characterisation of the compounds could not be accomplished.
†Based on 1H NMR spectroscopy of the crude extracted reaction mixture.
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HRMS confirmed the two compounds possessed the correct mass (for AmD), however,
the 1H NMR spectroscopic data did not match those of 5′,6′-epi,epi-AmD (69) or the
putative (7′Z)-isomer. As 10′-epi-AmD (64) is the enantiomer of 69, it suggests neither of
the compounds is 64 or its (7′Z)-isomer. 1H and 13C NMR spectra from earlier products
(after the formation of the macrocycle) in the 10′-epi- and 5′,6′-epi,epi-AmD syntheses are
identical, indicating that isomerisation occured during the acidic deprotection reaction.
The 1H NMR spectroscopy suggests the most plausible to be epimerisation of the allylic
alcohol, and E/Z-isomerisation of the 7′-alkene, as proposed to have occurred in the
synthesis of 69. The products were tentatively assigned as 5′,10′-epi,epi-AmD (100) and
its (7′Z)-isomer (101) based on the 1H NMR spectrum (Figure 5.1).
101 100
Figure 5.1. 1H NMR spectrum of the putative 10′-epi-AmD synthesis products 100 and
101 (500 MHz, acetone-d6).
1H NMR provides circumstantial evidence for the C6′-epimerisation, predominately
because changes to the 1H NMR spectrum expected from other plausible isomerisation
mechanisms (e.g. migration of the allylic alcohol, or 7′-alkene) were not observed. The
1H NMR spectrum displayed four minor peaks with 3JH,H′ couplings of ∼15.0 Hz (at
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6.81, 6.18, 5.60 and 5.49 ppm), indicating the minor component contains four (E)-alkene
protons. The minor peak at 4.68 ppm was attributed to the C6′-proton, and the minor peak
at 5.28 ppm (partially obscured by the corresponding peak of the major component) was
attributed to the C10′-proton. Of the major peaks in the 1H NMR spectrum, two showed
3JH,H′ couplings of ∼15.0 Hz (at 6.95 and 5.79 ppm), indicating the major compound
contains at least two (E)-alkene protons. The other two alkene protons were assigned
to peaks at 5.98 and 5.93 ppm, with their largest 3JH,H′ values measured to be 15.3 and
8.3 Hz, respectively. Unfortunately, due to the poor resolution and overlapping of these
peaks, their coupling constants and splitting patterns could not be accurately determined.
Proton signals at 5.36 and 4.32 ppm were tentatively attributed to the C10′-and C6′-
protons, respectively.
Epimerisation of the allylic alcohol could occur through acid–catalysed loss of water
at the C6′-position, and subsequent nucleophilic attack by water through a SN1-like
substitution mechanism to reform the alcohol with inverted stereochemistry (Scheme 5.7).
In the proposed mechanism, protonation and subsequent loss of the allylic alcohol would
form a resonance stabilised carbocation that could potentially form a protonated epoxide
through nucleophilic attack by the C5′-hydroxyl. As this protonated epoxide retains the
stereochemistry of the C5′-hydroxyl, it would block the top face of the molecule, causing
the SN2 substitution by water to only occur on the bottom face and lead to exclusive
formation of the (6′S)-product. Epimerisation at the C5′-position was also considered,
however, without the potential resonance stabilisation of the carbocation, this route would
be less favoured.
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Scheme 5.9. Proposed C6′-epimerisation mechanism.
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It is unknown why the putative epimerisation/isomerisation occurred to such an extent in
the 10′-epi-AmD system, while only slight E/Z-isomerisation occurred in the 5′,6′-epi,epi-
AmD system. The most logical reason would be due to variation in reaction conditions.
While both reactions were left for 2 days at room temperature, the 5′,6′-epi,epi-AmD
reaction mixture was 7.4 mM solution and the 10′-epi-AmD reaction mixture was 10.0
mM in 1:1 v/v methanol/1M hydrochloric acid solution. However, such an exaggerated
difference would not be expected from the slight variation in reaction conditions.
In the hope of gaining a greater insight into these experimental observations, computation
studies were done to calculate the lowest energy conformations of the final products.
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Chapter 6
Computational Studies
Two issues arose during the syntheses outlined in previous chapters: a varying degree
of isomerisation during the final deprotection of AmD and its analogues, and the
significantly different polarity of the 10′-epi-AmD synthesis product. To help rationalise
these experimental observations, computational calculations were performed to predict
the lowest energy conformation of the final products and their relative energies. Included
in these calculations were the two expected 10′-epi-AmD isomers (64 and 102) and
the proposed isomerisation products, the 6′,10′-epi,epi-AmD isomers (100 and 101)
(Figure 6.1). Using the Spartan© program, conformational searches were conducted to
determine the equilibrium conformation of each structure at ground state using molecular
mechanics force field (MMFF), with up to a limit of 70 000 structures examined. Density
functional theory (DFT) calculations were used to determine the self-consistent field
(SCF) energies of the resultant structures. These were preformed by employing the Becke
three-parameter with Lee-Yang-Parr (B3LYP) hybrid Hartree-Fock-density functional
method with a 6-31G* basis set for the ground state structure in a vacuum.
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Figure 6.1. 10′-epi-AmD and 6′,10′-epi,epi-AmD isomers.
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6.1 Calculated Energy of Lowest Energy Conformers
Comparing the energies of the lowest energy conformations of AmD and its analogues led
to some interesting observations. In all cases, the (7′Z)-isomer was higher energy than the
E-isomer, but the degree of that energy difference decreased from AmD to 5′,6′-epi,epi-
AmD to 10′-epi-AmD to 6′,10′-epi,epi-AmD. Interestingly, the AmD E- and Z-isomers
were found to be the highest energy structures, while the 6′,10′-epi,epi-AmD isomers were
found to be the lowest energy structures. As expected for enantiomers, 10′-epi-AmD and
5′,6′-epi,epi-AmD were found to have identical energies (Table 6.1).
Table 6.1. SCF energies of the lowest energy conformations of AMD and
analogues
Compound SCF energy SCF energy Energy relative
(Hartrees) (kJ/mol) to AmD (kJ/mol)
AmD -1150.4686 -3020555.25 0
(7′Z)-AmD -1150.4641 -3020543.43 +11.82
10′-epi-AmD -1150.4703 -3020559.82 -4.57
(7′Z)-10′-epi-AmD -1150.4671 -3020551.37 +3.88
5′,6′-epi,epi-AmD -1150.4703 -3020559.82 -4.57
(7′Z)-5′,6′-epi,epi-AmD -1150.4671 -3020551.37 +3.88
6′,10′-epi,epi-AmD -1150.4721 -3020564.59 -9.35
(7′Z)-6′,10′-epi,epi-AmD -1150.4697 -3020558.16 -2.91
The energy difference between the E/Z-isomers of the 5′,6′-epi,epi- and 10′-epi-AmD
series is slightly lower than that of the natural AmD series, 8.45 kJ/mol compared with
11.82 kJ/mol. This indicates that should an E/Z-isomer equilibrium exist, a greater ratio
of the Z-isomer would be expected in the 5′,6′-epi,epi- and 10′-epi-AmD series relative
to AmD, assuming a similar activation energy for the transformation in each system.
However, it is unknown whether these energy differences are large enough to have a
significant effect on experimental observations. It also does not explain the extent of
isomerisation that occurred in the 10′-epi-AmD system compared with the 5′,6′-epi,epi-
AmD system. The most likely explanation for the varying degrees of isomerisation
between the different AmD analogues remains variation in reaction conditions. Also of
note is the lower energy of the 6′,10′-epi,epi-AmD analogues. This indicates that under
conditions which allow for epimerisation, the 6′-10′-epi,epi-AmD analogue would be the
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thermodynamically favoured product. Interestingly, the major product of the 10′-epi-
AmD deprotection is actually proposed to be the (7′Z)-isomer, which may be a result of
kinetic rather than thermodynamic factors.
6.2 Structural Analysis of Lowest Energy Conformers
The structures of the lowest energy conformers were then analysed and compared. It
was hoped this would provide insight into the origin of varying chemical properties
between analogues. The structure of the (7′Z)-isomer of AmD is omitted as it was not
experimentally observed.
When viewed along the plane of the aromatic ring, the macrocycle of AmD has a closed,
bent structure (Figure 6.2). The structure is consistent with the expected intramolecular
hydrogen bonding between the C2-hydroxyl and the lactone carbonyl, which is indicated
by the chemical shift and peak shape (δ 11.66, sharp singlet) of the C2-hydroxyl proton in
the 1H NMR spectrum. This may retain the co-planarity of the carbonyl and the aromatic
ring.
Figure 6.2. Lowest energy conformation of AmD.
The macrocycle of 5′,6′-epi,epi-AmD has a closed, bent structure when viewed along the
aromatic ring, highly similar to that of AmD, with the main variation occurring about the
diol moiety (Figure 6.3). This agrees with the 1H NMR spectra of the two compounds in
which the spectra were highly similar, excluding the peaks of the C5′- and C6′-protons.
As with AmD, the lactone carbonyl appeared to be in the plane of the aromatic ring with
the distance between the carbonyl and C2-hydroxyl indicating potential intramolecular
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hydrogen bonding. The (7′Z)-isomer was also calculated to adopt a similar conformation
(Figure 6.3).
Figure 6.3. Lowest energy conformations of 5′,6′-epi,epi-AmD (top) and
(7′Z)-5′,6′-epi,epi-AmD (bottom).
As expected, the structure of 10′-epi-AmD (64) is the mirror image of the 5′,6′-epi,epi-
AmD structure (69), and consequently, all the bond angles and lengths within the two
compounds are identical. The macrocycle of 64 was calculated to be bent below the
plane of the aromatic ring, in contrast with the previously analysed structures where the
macrocycles were bent above the plane of the aromatic ring when viewed from the same
angle. The (7′Z)-isomer of 10′-epi-AmD (not shown for simplicity) is also identical to its
5′,6′-epi,epi-AmD counterpart.
Figure 6.4. Lowest energy conformation of 10′-epi-AmD.
The calculated structure of 6′,10′-epi,epi-AmD more closely resembles that of 10′-epi-
AmD as the macrocycle is bent below the plane of the aromatic ring, as seen with
10′-epi-AmD. The structure also has a more open structure than the previously viewed
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structures. The distance between the C2-hydroxyl and the lactone carbonyl suggests
hydrogen bonding between these moieties.
Figure 6.5. Lowest energy conformations of 6′,10′-epi,epi-AmD (top) and
(7′Z)-6′,10′-epi,epi-AmD (bottom).
Comparison of the structures supports the experimental observations, where AmD and
5′,6′-epi,epi-AmD were observed to have a similar polarity, while the products from the
attempted synthesis of 10′-epi-AmD were found to be significantly more polar. The
increased polarity may be due to the rotation of the diol moiety below the plane of the
aromatic ring, compared with the structures of AmD and 5′,6′-epi,epi-AmD, where the
diol moiety is relatively aligned with the plane of the aromatic ring. This supports the
proposed assignment of the unknown compounds as 6′,10′-epi,epi-AmD and its (7′Z)-
isomer.
Variation in chemical properties may also arise from disruption of the C2-hydroxyl
hydrogen bonding system, which, as observed earlier for the C2 protected species, would
increases the polarity of the molecule. This could occur by inversion of the C10′-methyl
causing the lactone carbonyl to be rotated out of the plane of the aromatic ring. There
is some evidence for this hypothesis in the 1H NMR, with the peak correlating to the
C2-hydroxyl being shifted upfield. However, this hypothesis is not supported by the
calculated conformers. Additionally, as the peak is still observed as a sharp singlet in
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the 1H NMR, indicating there is still a stable hydrogen bonded system, it is unknown
whether the hydrogen bonding would be sufficiently disrupted to alter the properties of
10′-epi-AmD as significantly as was observed experimentally. Analysis of the calculated
structures suggests intramolecular hydrogen bonding may also occur between the C5′- and
C6′-hydroxyls. The distance between the C5′-hydroxyl proton and C6′-hydroxyl oxygen
is around 2.0–2.1 A˚, and the dihedral angle between the hydroxyls is around 45–55◦ in all
the structures, including the 6′,10′-epi,epi-AmD isomers, where the hydroxyls are rotated
to align with each other. Although not predicted by the calculated structures, disruption
of this hydrogen bonding is another possible source of the differing polarity between the
compounds.
In summary, the energies of the conformers calculated in these computational experiments
suggests isomerisation of 5′,6′-epi,epi and 10′-epi-AmD to their Z-isomers is more
favoured relative to that of AmD under equilibrium conditions. However, it is unknown
if these energy differences are large enough to have a significant effect on experimental
observations or whether the energy barrier is surmountable. The calculated structures
were found to agree with the experimental properties, in that the structural similarity
between the calculated AmD structure and that of 5′,6′-epi,epi-AmD was consistent with
the similarity in their 1H NMR spectra and their chemical properties.
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Chapter 7
Attempted Synthesis of Late-Stage Aigialomycin D
Analogues
The synthesis of three late-stage analogues, 6′-oxo-AmD (70), 5′,6′-cyclopropyl AmD
(71) and 5-chloro-AmD (65) were pursued. It was intended that these analogues could
be synthesised by functionalisation of late intermediates in the natural AmD synthesis,
limiting the number of new reaction sequences that would be required.
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5',6'-Cyclopropyl-AmD 71
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HO
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5-Chloro-AmD 65
Cl
Figure 7.1. Proposed late-stage AmD analogues
7.1 Attempted Synthesis of 6′-oxo-AmD (70)
It was proposed that the allylic alcohol of AmD could be selectively oxidised with either
DDQ or manganese dioxide to afford oxo-AmD 70. DDQ was the preferred oxidising
agent as manganese dioxide is known to cause C-C bond cleavage in 1,2-diol systems.83–86
Also, manganese dioxide–catalysed oxidations typically require vast excesses of the
reagent (30-40 eq.), which could potentially lead to over-oxidation to the 5′,6′-di-oxo
product. Reacting AmD with DDQ in dioxane at room temperature overnight was found
to afford multiple compounds∗ which were unable to be separated and characterised. It
is unknown whether any of the desired enone was present in this mixture. Selective
oxidation of the allylic alcohol was then attempted by reacting AmD in a solution of
manganese dioxide at room temperature overnight. Again, a complex mixture of products
was obtained, from which none of the desired product could be isolated.
∗Determined by 1H NMR spectroscopy of the crude reaction mixture, which displayed various peaks
characteristic of AmD with slightly different chemical shifts.
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Scheme 7.1. Attempted synthesis of 6′-oxo-AmD 70.
7.2 Attempted synthesis of 7′,8′-cyclopropyl AmD (71)
It was proposed cyclopropyl AmD 71 could be synthesised by Simmons–Smith cyclo-
propanation of pre-Ramberg-Ba¨ckland alkene 59. However, all attempted Simmon-Smith
reactions were unsuccessful, with only starting material isolated. First, the prototype
Simmons–Smith method was tried.87 This uses a zinc/copper couple and diiodomethane
to form the reactive species (iodomethylzinc iodide, the Simmons–Smith reagent) in situ,
which then reacts with the alkene to form a cyclopropane. Formation of the Simmons–
Smith reagent was attempted by sonication of a solution of the zinc/copper couple
and diiodomethane in diethyl ether for one hour, to which a solution of alkene 59 in
diethyl ether was added. Only starting material was isolated from this reaction. It was
hypothesised that the lack of reaction could be due to the quality of the zinc/copper
couple. Therefore, the Furakawa modification of the Simmons–Smith reaction, which
employs an alternative zinc reagent (diethyl zinc) to form the Simmons–Smith reagent,100
was investigated. Two separate reactions were tried in which a solution of alkene 59 was
treated with diiodomethane and either a 1 M solution of diethyl zinc, or neat diethyl
zinc, with both reactions affording only starting material. It was then hypothesised that
the allylic alcohol of AmD (4) itself may be more reactive towards the Simmons–Smith
reagent than the allylic ether of protected compound 59. Thus, the reaction was attempted
by adding a solution of AmD (4) in DMF to a solution of diethyl zinc and diiodomethane
in dichloromethane, again with no success. Addition of diiodomethane to a solution of
diethyl zinc and AmD in DMF again led to no observable reaction.
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Scheme 7.2. Attempted Simmons–Smith cyclopropanations of alkenes 59 (top) and 4
(bottom).
7.3 Attempted Synthesis of 5-chloro-AmD (65)
Chlorination of the C5-position of AmD was also attempted. Previous syntheses of
C5-Cl containing RALs suggested electrophilic aromatic substitution would favour the
C5-position of the aromatic ring.72,101–103 The chlorination was attempted by addition of
N-chlorosuccinimide (NCS) and iron (III) chloride to a solution of AmD in dioxane.103
Unfortunately, no reaction was observed.
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Scheme 7.3. Attempted synthesis of 5-chloro-AmD 65.
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Chapter 8
Conclusions and Future Work
8.1 Concluding Remarks
Driven by the emerging biological value of RALs, the synthesis of five AmD analogues
was undertaken. These analogues included two diastereomers of AmD, 5′,6′-epi,epi-AmD
(69) and 10′-epi-AmD (64), as well as analogues possessing modified functional groups,
6′-oxo-AmD (70), 7′,8′-cyclopropyl AmD (71) and 5-chloro-AmD (65). To aid in the
synthesis of these, and future analogues, research began with optimisation of various
elements of the AmD synthesis previously developed.63
Optimisation of the methyl orsellinate synthesis had limited success, with its highest yield
being 66%, compared with 40% yield observed previously, however, the reaction was
found to be inconsistent, with repeat attempts yielding between 20–60%. The synthesis
of the thioacetate 43 was also optimised to a seven-step procedure affording a 38% yield,
an improvement on the 28% yield, eight step procedure used previously. Various other
minor optimisations were also developed.
5′,6′-epi,epi-AmD (69) was successfully synthesised from D-ribose in 15 steps (longest
linear sequence) in an overall yield of 3%. The synthesis was achieved by preparing the
enantiomer of a key intermediate in the natural AmD syntheis, α,β-unsaturated ester 72
(prepared in three steps from D-ribose with an overall yield of 66%). This enantiomeric
intermediate could then be employed in the natural AmD synthetic route to afford the
desired analogue. A significant by-product of this synthesis was presumed to be the (7′Z)-
isomer 93, that is proposed to be formed via acid-catalysed isomerisation during the final
deprotection step.
The synthesis of 10′-epi-AmD (64) was attempted through a divergent synthesis, in which
(R)-4-penten-2-ol, the enantiomer of the natural AmD synthesis chiral starting material,
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was empoyed to provided the desired (10′S) stereochemistry. While the synthesis was
successful, the product was found to isomerise during the final acidic deprotection step,
leading to the isolation of two unknown isomers of AmD, and none of the desired 10′-
epi-AmD. As all attempts to separate the compounds were unsuccessful, characterisation
was not possible. However, based on 1H NMR spectroscopy the mixture of compounds
was tentatively assigned as 6′,10′-epi,epi-AmD (100) and its (7′Z)-isomer (101).
All attempts at synthesising the three structural analogues were unsuccessful. It was
proposed 6′-oxo-AmD (70) could be synthesised by selective oxidation of the C6′-
hydroxyl of AmD with either DDQ or manganese dioxide. However, the use of
either reagent afforded a complex mixture of products that could not be separated and
characterised. Selective cyclopropanation of the 7′-alkene was attempted on both pre-
and post-Ramberg-Ba¨cklund substrates with various Simmons-Smith cyclopropanation
conditions. Unfortunately, only starting material was isolated from all of these reactions.
Attempted chlorination of the C5-position of AmD with NCS and iron (III) chloride was
also unsuccessful, returning only starting material.
Thus, one major goal (the synthesis of 5′,6′-epi,epi-AmD ) and various minor goals of
this research project have been achieved, affording analogues of AmD which will undergo
biological testing to provide valuable SAR information of the AmD structure. Synthetic
methodology has also been developed, which could potentially aid in the future syntheses
of new and exciting AmD analogues.
8.2 Future work
There is huge potential for the synthesis of additional AmD analogues. After biological
testing of the analogues synthesised in this research project to determine the effect
of inversion of the three AmD stereo-centres, the synthesis of more elaborate second
generation analogues may be undertaken. This could include the enantiomer of AmD,
5′,6′,10′-epi,epi,epi-AmD, which could potentially be prepared by combining the syn-
thetic methodology developed in the synthesis of 5′,6′-epi,epi and 10′-epi-AmD. The
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analogue studies could then move on to modification of functional groups around the
structure, towards improving the drug-like properties of the compound.
Based on research by Shen et al. in the field of RAL analogue synthesis,48–50 a
useful series of analogues could involve modifications at the C4-position of AmD. The
modifications published in these papers would provide a good starting point for this
series of analogues, in which their synthetic methodology could be adapted to the VUW
synthetic strategy (Scheme 8.1). This would involve the synthesis of a range of methyl
orsellinate analogues which could then be used in the VUW AmD synthesis.
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Scheme 8.1. Examples of possible C2-analogues of AmD.
Further work could also be performed on the synthesis of the 6′-oxo-AmD (70) and
5-chloro-AmD (65) analogues. The selective allylic oxidation of the C6′-hydroxyl of
AmD could potentially be achieved through optimisation of the reaction with DDQ
or manganese dioxide, or by employing an alternate oxidising agent such as barium
manganate. Alternative chlorination methods which have been used in the synthesis of
other RALs could potentially be used to selectively chlorinate the C5-position of AmD.
These include the use of chlorinating reagents sulfuryl chloride,104–106 or hypochlorous
acid.101
An important aspect in the future synthesis of AmD analogues is the optimisation of the
final deprotection step. As observed in this research, the current reaction conditions can
lead to significant isomerisation and subsequent loss of material. Therefore, development
of milder deprotection conditions will be a priority in future syntheses of AmD analogues.
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Chapter 9
Experimental
9.1 General Experimental Details
All reactions were performed by stirring under argon in oven-dried glassware using dry
solvents and standard syringe techniques. Tetrahydrofuran (THF) and dichloromethane
(CH2Cl2) were freshly distilled from the sodium benzophenone ketyl radical and calcium
hydride, respectively, prior to use. Triethylamine (NEt3) and acetonitrile (MeCN) were
distilled from calcium hydride; toluene and methanol (MeOH) were distilled from
sodium, and stored in a dry bottle under argon. Anhydrous diethyl ether (Et2O) was
purchased and stored over sodium. Anhydrous dimethylformamide (DMF) was purchased
from Aldrich Chemical Company and used without further purification. All reagents
used were available from laboratory stocks and purified as necessary, or purchased from
standard chemical suppliers. Analytical thin layer chromatography (TLC) was carried out
using aluminium backed TLC plates pre-coated with silica UV254 and visualised by UV
radiation (254 nm) and anisaldehyde dip. Flash column chromatography was carried out
using silica gel 60 (220–240 mesh) with solvent systems as indicated. Microwave-assisted
reactions were carried out in a Milestone Microsynth reactor, monitored by a fibre optic
temperature and pressure probe.
1H and 13C NMR spectra were recorded on either a Varian Unity Inova 300 (300 MHz
for 1H and 75 MHz for 13C), or a Varian Unity Inova 500 (500 MHz for 1H and 125
MHz for 13C) spectrometer. All chemical shifts (δ) were referenced to residual solvent
peaks (CDCl3:
1H - 7.26 ppm, 13C - 77.0 ppm; d6-acetone: 1H - 2.05 ppm, 13C - 29.8
ppm; d4-MeOH: 1H - 3.31 ppm, 13C - 49.00 ppm). Optical rotation was measured on a
Perkin-Elmer Polarimeter at the sodium D line (589 nm). High resolution mass spectra
(HRMS) were recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer using
electrospray ionization in the positive mode.
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9.2 Experimental Details for the Synthesis of Reagents
Copper (I) chloride: Granulated copper (2.0 g) was added to a solution of CuCl2 (3.2
g) in conc. HCl (12.0 mL) and refluxed until a clear solution was formed (ca. 1 h). The
solution was then filtered through a pad of Celiter into a Buchner funnel charged with an
ice water slurry (ca. 100 mL) and conc. H2SO4 (0.5 mL) forming a white precipitate. The
white precipitate was immediately collected on a Buchner funnel and washed with water
(ca. 20 mL), MeOH (ca. 20 mL), Et2O (ca. 20 mL) and dried in vacuo to afford CuCl as
a white powder which stored under argon.
Potassium tert-butoxide: Freshly cut potassium metal (0.50 g, washed in hexanes) was
added to a solution of freshly distilled t-BuOH (10 mL) stirring under argon at rt. After 24
h the solvent was removed in vacuo affording t-BuOK (1.30 g) as a white powder, which
was stored under argon.
9.3 Experimental Details for Chapter 2
Methyl orsellinate (46)
OMe
OH
HO
O
Methyl acetoacetate (2.00 mL, 18.53 mmol) was added to a stirred
solution of NaH (1.12 g, 27.79 mmol, 60% in mineral oil) in THF
(40 mL) at 0 ◦C and allowed to warm to rt. over 20 min. The solution was then cooled
to –78 ◦C, n-BuLi (8.80 mL, 17.61 mmol, 2.0 M in cyclohexane) added and the solution
allowed to warm to rt. After 17 h the solution was refluxed for 12 h, cooled to 0 ◦C, slowly
quenched with MeOH (20 mL) and then acidified to pH 5 with glacial AcOH (ca. 5 mL)
and warmed to rt. After 18 h the reaction mixture was concentrated in vacuo, extracted
with EtOAc (4 x 40 mL), the combined organic layers dried over MgSO4, filtered and
the solvent removed in vacuo to yield a red solid, which was purified by flash column
chromatography (silica, 2:1 hexanes/EtOAc) to yield the title compound as a white solid
(1.01 g, 60%). RF = 0.45 (2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) 11.75 (s,
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1H), 6.25 (d, J = 2.5 Hz, 1H), 6.21 (d, J = 2.5 Hz, 1H), 5.50 (s, 1H), 3.89 (s, 3H), 2.46 (s,
3H). The spectral data matched those reported in the literature.65
Methyl 2,4-bis(acetyloxy)-6-methylbenzoate (103)
OMe
OAc
AcO
O
NEt3 (2.31 mL, 16.47 mmol) followed by Ac2O (1.04 mL, 10.98
mmol) were added to a stirred solution of methyl orsellinate (500
mg, 2.74 mmol) in CH2Cl2 (8 mL) and left for 16 h. The reaction mixture was then
quenched with sat. NaHCO3 (15 mL), and the organic layer separated, dried over MgSO4,
filtered and evaporated to give a clear solution, which was purified by flash column
chromatography (silica, 3:1 hexanes/EtOAc) to yield the title compound as a white solid
(708 mg, 97%). RF = 0.30 (2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.88 (d,
J = 2.2 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H), 3.85 (s, 3H), 2.37 (s, 3H), 2.25 (s, 3H), 2.23 (s,
3H). The spectral data matched those reported in the literature.63
Methyl 2,4-bis(acetyloxy)-6-(bromomethyl)benzoate (44)
OMe
OAc
AcO
O
Br
NBS (370 mg, 2.65 mmol) and benzoyl peroxide (75 mg, 0.2 mmol)
were added to a refluxing solution of orsellinate 103 (565 mg, 2.12
mmol) in CCl4 (20 mL) in five portions over 8 h, and left stirring at
reflux. After 1 h the solution was cooled to 0 ◦C, filtered and the concentrated in vacuo to
give a yellow oil, which was purified by flash column chromatography (silica, CH2Cl2) to
yield the title compound as a white solid (597 mg, 81 %). RF = 0.48 (CH2Cl2). 1H NMR
(500 MHz, CDCl3) δ 7.10 (d, J = 2.2, 1H), 6.93 (d, J = 2.2, 1H), 4.60 (s, 2H), 3.90 (s, 3H),
2.27 (s, 3H), 2.24 (s, 3H). The spectral data matched those reported in the literature.63
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9.4 Experimental Details for Chapter 3
Methyl-2,3-O-(1-methylethylidene)-β-D-ribofuranoside (78)
O
O O
MeO OH
AcCl (95 µL, 1.33 mmol) was added dropwise to a solution of D-ribose
(2.00 g, 13.33 mmol) in MeOH (8.0 mL) and Me2CO (8.0 mL). The
solution was then refluxed for 12 h. The reaction was then quenched
with sat. NaHCO3 (5 mL) and the organic solvents concentrated in vacuo. The aqueous
solution was then extracted with EtOAc (2 x 20 mL) and the combined organic washings
dried over MgSO4, filtered and concentrated in vacuo to yield the title compound as
a colourless oil (2.18 g, 80%), which was deemed sufficiently pure by 1H NMR and
subsequently used without further purification. RF = 0.45 (2:1 hexanes/EtOAc). 1H NMR
(500 MHz, CDCl3)) δ 4.97 (s, 1H), 4.84 (d, J = 5.9 Hz, 1H), 4.59 (d, J = 5.9 Hz, 1H),
4.44 (t, J = 2.6 Hz, 1H), 3.70 (dt, J = 12.6, 2.4 Hz, 1H), 3.62 (ddd, J = 12.6, 10.7, 3.4 Hz,
1H), 3.44 (s, 3H), 3.23 (dd, J = 10.7, 2.6 Hz, 1H), 1.49 (s, 3H), 1.32 (s, 3H). The spectral
data matched those reported in the literature.66
Methyl 5-deoxy-5-iodo-2,3-O-(1-methylethylidene)-β-D-ribofuranoside (48)
O
O O
MeO I
PPh3 (2.46 g, 9.40 mmol) and imidazole (0.80 g, 11.75 mmol) were added
to a solution of sugar 78 (1.60 g, 7.83l) in toluene (30 mL) and MeCN (6
mL). To this solution, iodine (2.39 g, 9.40 mmol)) was added in portions
and the solution refluxed for 10 min then the solution allowed to cool to rt. The solution
was then diluted with Et2O (40 mL), washed with sat. Na2S2O3 (3 x 30 mL), water (2 x
40 mL), brine (40 mL), dried with MgSO4 and concentrated in vacuo to give a white solid
and oil. The mixture was suspended in 7:1 hexanes/EtOAc and filtered through a silica
plug and eluted with additional solvent. The filtrate was then concentrated in vacuo to
yield the product as a clear oil (2.04 g, 83%). RF = 0.68 (2:1 hexanes/EtOAc). 1H NMR
(500 MHz, CDCl3) δ 5.04 (s, 1H), 4.76 (d, J = 5.8 Hz, 1H), 4.62 (d, J = 5.9 Hz, 1H),
4.43 (dd, J = 10.1, 6.0 Hz, 1H), 3.36 (s, 3H), 3.28 (dd, J = 9.9, 6.0 Hz, 1H), 3.15 (t, J =
90
10.0 Hz, 1H), 1.47 (s, 3H), 1.32 (s, 3H). The spectral data matched those reported in the
literature.66
Methyl (2Z,4S,5R)-4,5-O-(1-methylethylidene) hepta-2,6-dienoate [(Z)-50] and Methyl
(2E,4S,5R)-4,5-O-(1-methylethylidene) hepta-2,6-dienoate [(E)-50]
O O
O
MeO
H
Activated zinc (1.80g, 27.63 mmol) was added to a solution of iodo-
sugar 48 (1.24 g, 3.95 mmol) in MeOH (20 mL), followed by AcOH
(67 µL) and the solution refluxed. After 3 h refluxing TLC confirm
the consumption of starting material. The solution was then allowed to cool to rt, filtered
through a wad of silica and eluted with additional MeOH. The solution was then cooled to
0 ◦C and methyl (triphenylphosphoranylidene) acetate (1.58 mg, 4.73 mmol) added and
the solution allowed to warm to rt. After 19 h TLC confirmed the consumption of starting
material and the solution was concentrated in vacuo, partitioned between EtOAc (60 mL)
and NH4Cl (60 mL). The aqueous layer was extracted with EtOAc (2 x 40 mL) and the
combined organic washings concentrated in vacuo. The crude mixture was suspended in
7:1 hexanes/EtOAc, filtered though a silica plug, eluted with additional solvent and the
filtrate concentrated in vacuo to yield a mixture of the title compounds as a clear liquid
[620 mg, 74% (Z/E = 5.1:1)]. RF = 0.60 [(Z-50], 0.50 [(E-50] (2:1 hexanes/EtOAc).
The compound was deemed sufficiently pure by 1H NMR and subsequently used without
further purification. 1H NMR (500 MHz, CDCl3) δ 6.79 (dd, J = 15.6 5.5 Hz, 1H), 6.20
(dd, J = 11.6, 7.5 Hz, 1H), 6.08 (dd, J = 15.6, 1.6 Hz, 1H), 5.90 (dd, J = 11.6, 1.6 Hz,
1H), 5.68 (ddd, J = 7.4, 7.2, 1.6 Hz, 1H), 5.66 (ddd, J = 17.1, 10.5, 7.2 Hz, 1H), 5.37 (dd,
J = 17.1, 1.5 Hz, 1H, 5.28 (ddd, J = 17.1, 1.7, 1.3 Hz, 1H), 5.15 (ddd, J = 10.3, 7.2, 1.1
Hz, 1H), 4.87 (tt, J = 7.1, 0.9 Hz, 1H), 4.78 (ddd, J = 7.0, 5.6, 1.6 Hz, 1H), 4.71 (tt, J =
7.0, 0.9 Hz, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 1.55 (s, 3H), 1.42 (s, 3H). The spectral data
matched those reported in the literature.63
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Methyl (4S,5R)-4,5-O-(1-methylethylidene) hept-6-enoate (51)
O O
O
MeO NaBH4 (1.51 g, 39.80 mmol) was added to a solution of α,β-
unsaturated esters 50 (1.77 g, 8.29 mmol), cyclohexene (3.36 mL,
33.17 mmol) and CuCl (657 mg, 6.33 mmol) in MeOH (130 mL)
stirring at −78 ◦C. After 2 h the solution was concentrated in vacuo and partitioned
between sat. NH4Cl (100 mL) and Et2O (100 mL). The aqueous layer was separated and
further extracted with Et2O (3 x 30 mL). The combined organic layers were then dried
over MgSO4, filtered and concentrated in vacuo to yield the title compound as a clear
liquid. (1.70 g, 95%). RF = 0.45 (2:1 hexanes/EtOAc). The compound was deemed
sufficiently pure by 1H NMR and subsequently used without further purification. 1H
NMR (500 MHz, CDCl3) δ 5.82 (ddd, J = 17.2, 10.3, 7.6 Hz, 1H), 5.34 (ddd, J = 17.1,
1.7, 1.1 Hz, 1H), 5.26 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 4.54 (dd, J = 7.5, 6.4 Hz, 1H),
4.16 (ddd, J = 8.8, 6.2, 5.4 Hz, 1H), 3.67 (s, 3H), 2.49 (ddd, J = 16.3, 8.3, 6.4 Hz, 1H),
2.40 (ddd, J = 16.4, 8.5, 7.4 Hz, 1H), 1.80–1.70 (m, 2H), 1.47 (s, 3H), 1.36 (s, 3H). The
spectral data matched those reported in the literature.63
(4S,5R)-4,5-O-(1-Methylethylidene) hept-6-en-1-ol (104)
O O
HO
A solution of ester 51 (1.70 g, 7.93 mmol) in Et2O (40 mL) was added
dropwise over 10 min to a solution of LiAlH4 (1.51 g, 39.67 mmol)
in Et2O (80 mL) stirring at −10 ◦C. After 15 min, TLC implied the
consumption of starting material. The reaction was then quenched with wet NaSO4,
filtered through a pad of Celiter and concentrated in vacuo to yield the title compound as
a colourless liquid (1.37 g, 93%). RF = 0.15 (2:1 hexanes/EtOAc). The compound was
deemed sufficiently pure by 1H NMR and subsequently used without further purification.
1H NMR (500 MHz, CDCl3) δ 5.82 (ddd, J = 17.1, 10.3, 7.8 Hz, 1H), 5.30 (ddd, J = 17.1,
1.6, 1.1 Hz, 1H), 5.24 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 4.52 (dd, J = 7.4, 6.7 Hz, 1H),
4.18 (ddd, J = 8.5, 6.2, 5.0 Hz, 1H), 3.68 (t, J = 5.8 Hz, 2H), 1.91 (s, 1H), 1.80–1.60 (m,
2H), 1.55 (m, 2H), 1.50 (s, 3H), 1.38 (s, 3H). The spectral data matched those reported in
the literature.63
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(4S,5R)-4,5-O-(1-Methylethylidene) hept-6-en-1-methanesulfonate (105)
O O
MsO
MsCl (0.86 mL, 11.04 mmol) was added to a solution of alcohol 104
(1.37 g, 7.36 mmol), NEt3 (2.07 mL, 14.72 mmol) and DMAP (90
mg, 0.74 mmol) in CH2Cl2 stirring at 0
◦C and the solution allowed
to warm to rt. After 20 h, the solution was concentrated in vacuo, the residue dissolved in
EtOAc (100 mL), washed with water (50 mL) and brine (50 mL). The combined aqueous
layers were then extracted with EtOAc (2 x 50 mL). The combined organic layers where
then washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo
to give a yellow liquid, which was purified by flash column chromatography (silica, 1:1
hexanes/EtOAc) to yield the title compound as a colourless oil (1.92 g, 99%). RF = 0.20
(2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 5.84 (ddd, J = 17.1, 10.3, 7.7 Hz,
1H), 5.33 (ddd, J = 17.1, 1.6, 1.1 Hz, 1H), 5.30 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 4.57
(dd, J = 7.5, 6.4 Hz, 1H), 4.30 (dt, J = 9.9, 6.3 Hz, 1H ), 4.25 (ddd, J = 9.8, 7.0, 6.0 Hz,
1H), 4.19 (ddd, J = 9.0, 6.2, 4.7 Hz, 1H), 3.05 (s, 3H), 1.99 (tdd, J = 12.3, 9.2, 6.2 Hz,
1H), 1.91–1.82 (m, 1H), 1.60–1.52 (m, 2H), 1.50 (s, 3H), 1.39 (s, 3H). The spectral data
matched those reported in the literature.63
(4S,5R)-4,5-O-O-(1-Methylethylidene) hept-6-en-1-thioacetate (43)
O O
AcS
KSAc (1.06 g, 9.21 mmol) was added to a stirred solution of mesylate
105 (2.03 g, 7.67 mmol) in DMF (65 mL) at 0 ◦C and the solution
allowed to warm to rt. TLC suggested the consumption of starting
material after 20 h. The reaction was then partitioned between EtOAc (150 mL) and
water (150 mL). The organic layer was separated, washed with sat. NaHCO3 (3 x 50
ml), followed by brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo
to give a brown liquid, which was purified by flash column chromatography (silica, 7:1
hexanes/EtOAc) to yield the title compound as a faint brown liquid (1.70 g, 91%). RF =
0.55 (2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 5.79 (ddd, J = 17.1, 9.7, 7.8
Hz, 1H), 5.30 (d, J = 17.1 Hz, 1H), 5.24 (d, J = 10.3 Hz, 1H), 4.49 (t, J = 6.9 Hz, 1H),
4.13 (m, 1H), 2.95–2.83 (m, 2H), 2.32 (s, 3H), 1.80–1.68 (m, 1H), 1.66–1.50 (m, 2H),
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1.49–1.41 (m, 1H), 1.47 (s, 3H), 1.36 (s, 3H). The spectral data matched those reported
in the literature.63
Methyl (6′S,7′R)-6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-dihydroxy-
benzoate (55)
OMe
OH
HO
O
S
O
O
A solution of thioacetate 43 (460 mg, 1.88 mmol) and resorcylic
bromoester 44 (650 mg, 1.88 mmol) in MeOH (40 mL) was
degassed by sonicating while flushing with argon for 10 minutes.
K2CO3 (651 mg, 4.71 mmol) was then added to the reaction
mixture. After 22 h, the reaction was concentrated in vacuo, the
crude product was dissolved in EtOAc (50 mL) and sat. NH4Cl
(50 mL), the aqueous layer separated and further extracted with EtOAc (3 x 25 mL).
The combined organic layers were then washed with brine (20 mL), dried over MgSO4,
filtered and concentrated in vacuo to give a brown oil, which was purified with flash
column chromatography (silica, gradient elution 5:1 to 2:1 hexanes/EtOAc) to yield the
title compound as a colourless oil (580 mg mg, 74%). RF = 0.40 (2:1 hexanes/EtOAc).
1H NMR (500 MHz, CDCl3) δ 11.68 (s, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.28 (d, J = 2.5
Hz, 1H), 5.79 (ddd, J = 17.2, 10.3, 7.8 Hz, 1H), 5.31 (ddd, J = 17.1, 1.7, 1.1 Hz, 1H),
5.25 (ddd, J = 10.3, 1.5, 0.9 Hz, 1H), 4.50 (dd, J = 7.7, 6.4 Hz, 1H), 4.10 (ddd, J = 9.1,
6.1, 4.3 Hz, 1H), 3.93 (d, J = 13.6 Hz, 1H), 3.93 (s, 3H), 3.87 (d, J = 13.6 Hz, 1H), 2.43
(t, J = 7.4 Hz, 2H), 1.76–1.66 (m, 1H), 1.65–1.50 (m, 2H), 1.49 (s, 3H), 1.50–1.40 (m,
1H), 1.38 (s, 3H). The spectral data matched those reported in the literature.63
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(Methyl (6′S,7′R)-6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-di-
(methoxymethoxy)benzoate (80)
OMe
MOMO
MOMO
O
S
O
O
NaH (64 mg, 1.60 mmol, 60% dispersion in mineral oil) was
added to a stirred solution of diol 55 (245 mg, 0.64 mmol)
in DMF (5 mL) at 0 ◦C. After 20 min MOMCl (145 µl, 1.92
mmol) was added and the solution allowed to warm to rt. After
2 h, the reaction was quenched with sat. NH4Cl (20 mL) and
extracted with Et2O (3 x 20 mL). The combined organic layers
were then washed with brine (30 mL), dried over MgSO4, filtered and concentrated in
vacuo to give a yellow oil, which was purified by flash column chromatography (silica,
gradient elution, 5:1 to 2:1 hexanes/EtOAc) to yield starting material (40 mg, 16%) as a
colourless oil and the title compound as a colourless oil (244 mg, 80%). RF = 0.30 (2:1
hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.73 (d, J = 2.2 Hz, 1H), 6.67 (d, J =
2.2 Hz, 1H), 5.78 (ddd, J = 17.1, 10.3, 7.8 Hz, 1H), 5.28 (ddd, J = 17.1, 1.6, 1.1 Hz, 1H),
5.21 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 5.16 (s, 2H), 5.15 (s, 2H), 4.46 (dd, J = 7.6, 6.4 Hz,
1H), 4.08 (ddd, J = 8.6, 6.1, 4.7 Hz, 1H), 3.88 (s, 3H), 3.70 (s, 2H), 3.47 (s, 3H), 3.46 (s,
3H), 2.48–2.40 (m, 2H), 1.77–1.67 (m, 1H), 1.60–1.43 (m, 3H), 1.46 (s, 3H), 1.34 (s, H).
The spectral data matched those reported in the literature.63
(6′S,7′R)-6-(6′,7′-O-(1′′-Methylethylidene)-2′-thianon-8′-enyl)-2,4-di-
(methoxymethoxy)benzoic acid (45)
OH
MOMO
MOMO
O
S
O
O
KOH (145 mg, 2.57 mmol) was added to a stirred solution of
ester 80 (242 mg, 0.51 mmol) in 2:1 MeOH/H2O (5 mL) and
then heated at 80 ◦C. After 4 days the solution was washed
with Et2O (5 mL), the aqueous layer acidified to pH = 6 with
10% KHSO3 (ca. 5 mL) and extracted with Et2O (3 x 15 mL).
The combined organic layers were then washed with brine (5
mL), dried over MgSO4, filtered and concentrated to give the crude product as a colourless
oil (220 mg). 1H NMR (500 MHz, CDCl3) δ 6.79 (d, J = 2.2 Hz, 1H), 6.75 (d, J = 2.2
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Hz, 1H), 5.81 (ddd, J = 17.2, 10.2, 7.8 Hz, 1H), 5.30 (ddd, J = 17.1, 1.6, 1.0 Hz, 1H),
5.24 (s, 2H), 5.24 (dd, J = 10.3, 1.6, 0.8 Hz, 1H), 5.20 (s, 2H), 4.49 (dd, J = 7.6, 6.4 Hz,
1H), 4.14 (ddd, J = 8.4, 6.1, 4.6 Hz, 1H), 3.98 (d, J = 13.4 Hz, 1H), 3.94 (d, J = 13.4 Hz,
1H), 3.52 (s, 3H), 3.49 (s, 3H), 2.50 (t, J = 7.0 Hz, 2H), 1.76 (m, 1H), 1.66–1.50 (m, 3H),
1.49 (s, 3H), 1.36 (s, 3H). The spectral data matched those reported in the literature.63
(4S)-Pent-1-en-4-yl (6′S,7′R)-6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-
2,4-(dimethoxymethoxy)benzoate (56)
O
MOMO
MOMO
O
S
O
O
(R)-4-penten-2-ol (90 µL, 0.86 mmol) was added to a stirred
solution of PPh3 (473 mg, 1.81 mmol) and DIAD (358 µL,
1.81 mmol) in THF (15 mL) at 0 ◦C under argon. After 30
min, a solution of acid 45 (330 mg, 0.72 mmol) in THF (10
mL) was added and he solution allowed to warm to rt. After
24 h a small potion of silica was added to the solution and
the solvent removed in vacuo. The dry silica was then loaded on a silica column and
gradient eluted with 20:1 to 4:1 hexanes/EtOAc) to yield a crude product as a yellow oil,
which was purified by flash column chromatography (silica, gradent elution, 9:1 to 5:1
hexanes/EtOAc) to yield the title compound as a colourless oil (269 mg, 71%). RF = 0.55
(2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.72 (d, J = 2.2 Hz, 1H), 6.69 (d, J
= 2.1 Hz, 1H), 5.85 (dddd, J = 17.2, 10.2, 7.0, 7.0 Hz, 1H), 5.78 (ddd, J = 17.9, 10.3, 7.8
Hz, 1H), 5.28 (d, J = 17.1 Hz, 1H), 5.25–5.20 (m, 2H), 5.15 (s, 2H), 5.14 (d, J = 1.7 Hz,
2H), 5.13–5.07 (m, 2H), 4.46 (dd, J = 7.3, 6.6 Hz, 1H), 4.09 (ddd, J = 8.5, 6.0, 4.8 Hz,
1H), 3.71 (q, J = 13.7 Hz, 2H), 3.46 (s, 3H), 3.45 (s, 3H), 2.46 (qt, J = 12.9, 6.6 Hz, 3H),
2.40–2.33 (m, 1H), 1.72 (m, 1H), 1.60–1.40 (m, 3H), 1.46 (s, 3H), 1.34 (s, 3H), 1.34 (d,
J = 6.2 Hz, 3H). The spectral data matched those reported in the literature.63
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(4S)-Pent-1-en-4-yl (6′S,7′R)-6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-
2,4-(dimethoxymethoxy)benzoate 2′,2′-dioxide (57)
O
MOMO
MOMO
O
S
O O
O
O
m-CPBA (267 mg, 1.16 mmol, 77% w/w) was added to
a stirred solution of thioether 56 (269 mg, 0.53 mmol)
in CH2Cl2 (10 mL) at 0
◦C under argon. After 2 h TLC
suggested remaining starting material, excess m-CPBA
(38 mg, 0.17 mmol, 77% w/w) was added. After 1 h
the reaction was quenched with 20% Na2SO3 (20 mL), the aqueous layer separated
and further extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were
then dried over MgSO4, filtered and concentrated in vacuo to give a colourless oil,
which was purified by flash column chromatography (silica, gradient elution 2:1 to 1:1
hexanes/EtOAc) to give the title compound as a colourless oil (256 mg, 90%). RF = 0.20
(2:1 hexanes/EtOAc). [α]D22 = 54.3 (c 1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.87
(d, J = 2.2 Hz, 1H), 6.85 (d, J = 2,2 Hz, 1H), 5.85 (dddd, J = 17.1, 10.1, 7.0, 7.0 Hz, 1H),
5.78 (ddd, J = 17.7, 10.4, 7.9 Hz, 1H), 5.25–5.00 (m, 6H), 5.16 (s, 2H), 4.46 (t, J = 7.0
Hz, 1H), 4.38 (d, J = 14.1 Hz, 1H), 4.28 (d, J = 14.1 Hz, 1H), 4.12–4.07 (m, 1H), 3.46 (s,
3H), 3.45 (s, 3H). 3.02 (ddd, J = 13.9, 10.2, 5.7 Hz, 1H), 2.94 (ddd, J = 13.9, 10.1, 5.7
Hz, 1H), 2.51–2.44 (m, 1H), 2.42–2.35 (m, 1H), 2.02–1.91 (m, 1H), 1.89–1.80 (m, 1H),
1.52 (tdd, J= 11.2, 7.0, 3.9 Hz, 2H), 1.45 (s, 3H), 1.34 (d, J = 6.3 Hz, 3H), 1.33 (s, 3H).
The spectral data matched those reported in the literature.63
(5S,7E,9R,10S)-1,2-(3′,5′-Di-O-methoxymethyl)benzo-4-oxa-14-thia-3-oxo-5-methyl-
9,10-O-(1-methylethylidene)-pentadec-7-ene 14,14-dioxide (59)
MOMO
MOMO
O
O
S
O
OO
O
A 100 mL MW TeflonTM reaction vessel was charged
with a solution of Grubbs’ second generation catalyst (24
mg, 0.03 mmol) and diene 57 (155 mg, 0.28 mmol) in
CH2Cl2 (40 mL), flushed with argon and sealed. The
reaction was then heated to 75 ◦C over 2 min and held at this temperature for a further
28 min (see Appendix for a typical microwave heating profile). After cooling to rt. the
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reaction mixture was concentrated in vacuo to give a dark green oil, which was purified
three times by flash column chromatography (silica, 1:1 hexanes/EtOAc) to yield the title
compound as a colourless oil (111 mg, 75%). RF = 0.12 (2:1 hexanes/EtOAc). 1H NMR
(500 MHz, CDCl3) δ 7.16 (d, J = 2.2 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H), 5.71 (ddd, J =
15.2, 9.3, 4.3 Hz, 1H), 5.55 (ddd, J = 15.4, 9.4, 1.4 Hz, 1H), 5.29 (m, 1H), 5.21 (d, J =
6.8 Hz, 1H), 5.16 (t, J = 3.4 Hz, 1H), 5.16 (s, 2H), 4.47 (d, J = 15.3 Hz, 1H), 4.43 (dd,
J = 9.3, 5.8 Hz, 1H), 4.13 (d, J = 15.1 Hz, 1H), 4.11 (m, 1H), 3.47 (s, 3H), 3.47 (s, 3H),
2.83 (ddd, J = 14.6, 11.1, 5.3 Hz, 1H), 2.65 (m, 1H), .47 (m, 1H), 2.41 (dd, J = 15.5, 9.8
Hz, 1H), 1.75 (m, 1H),1.67 (m, 1H), 1.62–1.53 (m, 2H), 1.43 (s, 3H), 1.40 (d, J = 6.2 Hz,
3H), 1.32 (s, 3H). The spectral data matched those reported in the literature.63
(5′S,6′R,10′S)-2,4-Di-O-(methoxymethyl)-5′,6′-O-(1′′-methylethylidene)-
aigialomycin D (60)
MOMO
MOMO
O
O
O
O
KOH (285 mg, 5.07 mmol) was added to a stirred solution
of sulfone 59 (134 mg, 0.25 mmol) in t-BuOH (1.0 mL) and
CH2Cl2 (0.40 mL) under argon. CCl4 (98 µL) was then added
dropwise and the solution heated to 35 ◦C. After 30 min TLC
suggest the consumption of starting material. The solvent was then removed in vacuo, the
crude mixture dissolved in EtOAc (10 mL) and sat. NH4Cl (10 mL), the layers separated
and the aqueous layer further extracted with EtOAc (2 x 10 mL). The combined organic
layers were then dried over MgSO4, filtered and concentrated in vacuo to give a yellow
oil, which was purified by flash column chromatography (silica, gradient elution 5:1 to
2:1 hexanes/EtOAc) to yield the title compound as a white solid (101 mg, 86%). RF =
0.40 (2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.81 (d, J = 2.1 Hz, 1H), 6.69
(d, J = 2.1 Hz, 1H), 6.24 (d, J = 15.8 Hz, 1H), 6.14 (ddd, J = 15.3, 9.6, 4.2 Hz, 1H), 5.74
(ddd, J = 15.3, 9.4, 3.5 Hz, 1H), 5.60 (ddd, J = 15.4, 9.7, 1.7 Hz, 1H), 5.34 (m, 1H), 5.20
(d, J = 6.7 Hz, 1H), 5.16 (s, 2H), 5.12 (d, J = 6.8 Hz, 1H), 4.57 (dd, J = 9.6, 5.4 Hz, 1H),
4.19 (ddd, J = 11.6, 5.4, 3.1 Hz, 1H), 3.46 (s, 3H), 3.46 (s, 3H), 2.58–2.44 (m, 2H), 2.31
(m, 1H), 2.11 (m, 1H), 1.80 (m, 1H), 1.49 (m, 1H), 1.47 (s, 3H), 1.37 (d, J = 6.3 Hz, 3H),
1.36 (s, 3H). The spectral data matched those reported in the literature.63
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Aigialomycin D (4)
OH
HO
O
O
OH
OH
Protected AmD 60 (15 mg, 0.04 mmol) was stirred in a solution
of in 1:1 v/v MeOH/ 1 M HCl (1 mL). After 3 days the reaction
mixture was extracted with EtOAc (3 x 5 mL), the combine
organic layers washed with brine (2 mL), dried over MgSO4,
filtered and evaporated in vacuo to give a yellow oil which was purified by flash column
chromatography (silica, gradient elution 1–5% MeOH/CH2Cl2 to yield AmD as a white
solid (6 mg, 67%). RF = 0.40 (10% MeOH/CH2Cl2). 1H NMR (500 MHz, d6-acetone)
11.66 (s, 1H), 7.15 (d, J = 15.9 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H), 6.28 (d, J = 2.0 Hz, 1H),
6.09 (ddd, J = 15.9, 5.7, 5.5 Hz, 1H), 5.88 (ddd, J = 15.6, 7.4, 1.6 Hz, 1H), 5.69 (ddd, J
= 15.6, 5.2, 1.2 Hz, 1H), 5.44 (m, 1H), 4.35 (d, J = 4.1 Hz, 1H), 3.63 (m, 1H), 2.57 (ddd,
J = 14.6, 7.4, 3.1 Hz, 1H), 2.43 (m, 1H), 2.36–2.32 (m, 2H), 2.14 (m, 1H), 1.59 (m, 1H),
1.37 (d, J = 6.4 Hz, 3H). The spectral data matched those reported in the literature.63
9.5 Experimental Details for Chapter 4
2,3-O-(1-methylethylidene)-α,β-D-ribofuranose (82)
O
O O
OHHO Conc. H2SO4 (36 µL, 0.66 mmol) was added dropwise to a solution
of D-ribose (1.00 g, 6.66 mmol) in Me2CO (15 mL). The reaction was
deemed complete by TLC after 1 h. The reaction was then neutralised
with solid NaHCO3, filtered and evaporated to give a clear oil, which was purified with
flash chromatography (silica, gradient elution 1:1 to 1:2 hexanes/EtOAc) to yield the title
compound as a clear oil [1.06 g mg, 84% (α:β 1:5.0)]. 1H NMR (500 MHz, CDCl3) δ
5.41(d, J = 5.4 Hz, 1H), 4.98 (d, J = 5.1 Hz, 1H), 4.83 (d, J = 5.9 Hz, 1H), 4.58 (d, J =
5.9 Hz, 1H), 4.41 (irregular t, J = 2.4 Hz, 1H), 3.7–3.8 (m, 2H), 1.58 (s, 3H) 1.49 (s, 3H),
1.40 (s, 3H), 1.32 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 112.1, 102.8, 87.7, 86.8, 81.6,
63.6, 26.35, 24.6. The spectral data matched those reported in the literature.73
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(4S,5S)-3,4-O-(1-Methylethylidene) hex-5-en-1,2-diol (83)
OH
O O
HO
KHMDS (13.60 mL, 6.78 mmol, 0.5 M in toluene), was added to a
solution of CH3PPH3Br (1857 mg, 5.20 mmol) in THF (20 mL) at
−78 ◦C. After 1 h a solution of sugar 82 (430 mg, 2.26 mmol) and
TMSCl (0.35 mL, 2.71 mmol) in THF (15 mL) at 0 ◦C were added and the solution
allowed to warm to rt. overnight. Solution cooled to 0◦C and acidified to pH 0-1and
left stirring. After 15 min TLC suggested complete TMS deprotection. The organic layer
was then separated, the aqueous layer extracted with EtOAc (3 x 30 mL). The combined
organic layers were then dried over MgSO4, filtered and evaporated in vacuo to give
a cream coloured solid, which was purified using flash column chromatography (silica,
gradient elution 1:1 to 1:2 hexanes/EtOAc) to yield the title compound as a clear oil (370
mg, 87%). RF = 0.08 (2:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 5.96 (ddd, J
= 17 Hz, 11 Hz, 6 Hz, 1 H), 5.41(d, J = 17 Hz, 1H), 5.26 ( d , J = 11 Hz, 1H), 4.65 (t, J
= 6 Hz , 1H ), 4.09 (dd, J = 6.4, 8.4 Hz, 1H), 3.75 (m, 1H), 3.62 (m, 2H), 3.20 (brs, 2H),
1.42 (s, 3H), 1.31 (s, 3H). The spectral data matched those reported in the literature.73
Methyl (2Z,4R,5S)-4,5-O-(1-methylethylidene) hepta-2,6-dienoate [(Z)-72] and Methyl
(2E,4R,5S)-4,5-O-(1-methylethylidene) hepta-2,6-dienoate [(E)-72]
O O
O
MeO
H
NaIO4 (841 mg, 3.93 mmol) was added to a solution of diol 83 (370
mg, 1.97 mmol) in MeOH (20 mL). After 3 h TLC suggested the
consumption of starting material. Silica gel was then added and the
solution stirred for 30 min, then filtered through a Celiter plug and eluted with MeOH
(20 mL). The solution was then cooled to 0 ◦C under argon and Ph3P−CHCO2CH3 (789
mg, 2.36 mmol) added and the solution allowed to warm to rt. After stirring overnight,
the solvent was evaporated in vacuo to give a yellow solid which was partitioned between
EtOAc (20 mL) and sat. NH4Cl (20 mL), the aqueous layer extracted with EtOAc (2 x 10
mL), the combined organic layers dried over MgSO4, filtered and evaporated in vacuo to
give a yellow solid which was purified with flash column chromatography (silica, gradient
elution, 10:1 to 5:1 hexanes, EtOAc) to yield the (Z)-isomer as a colourless oil and the (E)-
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isomer as colourless crystals [346 mg, 83% (E/Z = 1:5.1)]. A sample was further purified
by flash column chromatography (silica, gradient elution 10:1 to 5:1 hexanes/EtOAc) for
characterisation purposes to yield (E)-72 and (Z)-72. [(E)-72]: [α]D21 = +30.2 (c 1.00,
CHCl3). RF = 0.50 (2:1 hexanes:EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.79 (dd, J =
15.7, 5.6 Hz, 1H), 6.07 (dd, J = 15.7, 1.5 Hz, 1H), 5.69 (ddd, J = 17.1,10.3, 7.6 Hz, 1H),
5.36 (dd, J = 17.1, 1.5 Hz, 1H), 5.26 (ddd, J = 10.3, 1.5, 0.9 Hz, 1H), 4.78 (ddd, J = 7.0,
5.6, 1.6 Hz, 1H), 4.71 (tt, J = 7.0, 0.9 Hz, 1H), 3.75 (s, 3H), 1.55 (s, 3H), 1.41 (s, 3H).
[(Z)-72]: [α]D21 = -167.4 (c 3.00, CHCl3). RF = 0.59 (2:1 hexanes:EtOAc). 1H NMR
(500 MHz, CDCl3) δ 6.20 (dd, J = 11.5, 7.4 Hz, 1H), 5.90 (dd, J = 11.8, 1.7 Hz, 1H),
5.68 (ddd, J = 7.4, 7.2, 1.6 Hz, 1H), 5.66 (ddd, J = 17.1, 10.4, 7.3 Hz, 1H), 5.26 (ddd, J
= 17.1, 3.0, 1.7 Hz, 1H), 5.15 (ddd, J = 10.3, 1.6, 1.0 Hz, 1H), 4.86 (ddd, J = 8.3, 2.2, 1.0
Hz, 1H), 3.72 (s, 3H), 1.54 (s, 3H), 1.41 (s, 3H). The spectral data matched those reported
in the literature.63
Methyl (4R,5S)-4,5-O-(1-methylethylidene) hept-6-enoate (86)
O O
O
MeO NaBH4 (162 mg, 4.27 mmol) was added to a solution of esters 72
(189 mg, 0.89 mmol), CuCl (88 mg, 0.89 mmol) and cyclohexene
(0.36 mL, 3.56 mmol) in Et2O (5 mL) at −78 ◦C. After 30 min TLC
suggested remaining starting material, additional CuCl (9 mg, 0.09 mmol) and NaBH4 (7
mg, 0.18 mmol) added. After 15 min TLC suggested the consumption of starting material.
Solvent concentration in vacuo gave a black and white solid. The crude mixture was
partitioned between EtOAc (10 mL0 and sat. NH4Cl (10 mL), the aqueous layer separated
and extracted with EtOAc (2 x 5 mL). The combined organic layers were then dried over
MgSO4, filtered and concentrated in vacuo to give a yellow oil, which was purified with
flash column chromatography (silica, gradient elution, 15:1 to 9:1 hexanes/EtOAc) to
yield the title compound as a clear oil (167 mg, 88%). RF = 0.52 (2:1 hexanes:EtOAc).
[α]D21 = +27.2 (c 2.00, CHCl3). 1H NMR (500 MHz, CDCl3) δ 5.82 (ddd, J = 17.2,
10.5, 7.7 Hz, 1H), 5.34 (ddd, J = 17.1, 2.7, 1.2 Hz, 1H), 5.26 (ddd, J = 10.2, 1.4, 1.0 Hz,
1H), 4.54 (dd, J = 7.5, 6.4 Hz, 1H), 4.15 (ddd, J = 8.8, 6.2, 5.4 Hz, 1H), 3.68 (s, 3H), 2.50
(ddd, J = 16.3, 8.3, 6.4 Hz, 1H), 2.39 (ddd, J = 16.4, 8.5, 7.4 Hz, 1H), 1.80–1.70 (m, 2H),
1.47 (s, 3H), 1.36 (s, 3H). The spectral data matched those reported in the literature.63
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(4R,5S)-4,5-O-(1-Methylethylidene) hept-6-en-1-ol (87)
O O
HO
A solution of ester 86 (296 mg, 1.38 mmol) in Et2O (10 mL) was
added to a solution of LiAlH4 (315 mg, 8.29 mmol) in Et2O (15
mL) at −10 ◦C. After 30 min TLC suggested remaining starting
material, additional LiAlH4 (44 mg, 1.17 mmol) added. After 10 min TLC suggested
the consumption of starting material. Reaction quenched with wet NaSO4, dried with anh.
NaSO4 and concentrated in vacuo to yield the title compound as a clear oil (209 mg, 81%).
RF = 0.10 (2:1 hexanes/EtOAc). [α]D18 = +2.5 (c 1.00, CHCl3). The compound was
deemed sufficiently pure by 1H NMR and subsequently used without further purification.
1H NMR (500 MHz, CDCl3) δ 5.81 (ddd, J = 17.1, 10.3, 7.8 Hz, 1H), 5.29 (ddd, J = 17.1,
1.6, 1.1 Hz, 1H), 5.23 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 4.51 (dd, J = 7.4, 6.7 Hz, 1H),
4.17 (ddd, J = 8.5, 6.2, 5.0 Hz, 1H), 3.67 (t, J = 5.8 Hz, 2H), 1.91 (s, 1H), 1.80–1.60 (m,
2H), 1.55 (m, 2H), 1.49 (s, 3H), 1.37 (s, 3H). The spectral data matched those reported in
the literature.63
(4R,5S)-4,5-O-(1-Methylethylidene) hept-6-en-1-methanesulfonate: (106)
O O
MsO
MsCl (0.11 mL, 1.48 mmol) was added to solution of alcohol 87
(209 mg, 1.12 mmol mmol), NEt3 (0.24 mL, 0.27 mmol) and DMAP
(14 mg, 0.11 mmol) in CH2Cl2 (10 mL) at 0
◦C. TLC suggested the
consumption of starting material after 17 h. The solvent was then concentrated in vacuo
to give a yellow solid, which was partitioned between EtOAc (20 mL) and water (20
mL). The organic layer was then separated, washed with sat. NaHCO3 (10 mL), dried
over MgSO4, filtered and concentrated in vacuo to give a yellow oil, which was purified
by flash column chromatography (silica, 3:1 hexanes/EtOAc) to yield the title compound
as a clear oil (270 mg, 91%). RF = 0.25 (2:1 hexanes/EtOAc). [α]D21 = +6.1 (c 1.00,
CHCl3).
1H NMR (500 MHz, CDCl3) δ 5.84 (ddd, J = 17.1, 10.3, 7.7 Hz, 1H), 5.33
(ddd, J = 17.1, 1.6, 1.1 Hz, 1H), 5.30 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 4.57 (dd, J = 7.5,
6.4 Hz, 1H), 4.30 (dt, J = 9.9, 6.3 Hz, 1H ), 4.25 (ddd, J = 9.8, 7.0, 6.0 Hz, 1H), 4.19 (ddd,
J = 9.0, 6.2, 4.7 Hz, 1H), 3.01 (s, 3H), 1.99 (tdd, J = 12.3, 9.2, 6.2 Hz, 1H), 1.88–1.78
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(m, 1H), 1.60–1.52 (m, 2H), 1.52 (s, 3H), 1.40 (s, 3H). The spectral data matched those
reported in the literature.63
(4R,5S)-4,5-O-O-(1-Methylethylidene) hept-6-en-1-thioacetate (81)
O O
AcS
KSAc (58 mg, 0.51 mmol) was added to a solution of mesylate 106
(112 mg, 0.42 mmol) in DMF (4 mL) at 0 ◦C and allowed to warm
to rt. TLC suggested the consumption of starting material after 20
h. The reaction mixture was then partitioned between Et2O (10 mL) and water (10 mL).
The organic layer was then separated, washed with sat. NaHCO3 (2 x 5 mL), brine (5
mL), dried over MgSO4 and concentrated in vacuo to give a faint yellow liquid, which
was purified with flash column chromatography (silica, 10:1 hexanes/EtOAc) to yield the
title compound as a clear liquid (85 mg, 82%). RF = 0.60 (2:1 hexanes/EtOAc). [α]D21
= +11.5 (c 1.00, CHCl3).
1H NMR (500 MHz, CDCl3) δ 5.79 (ddd, J = 17.1, 9.7, 7.8
Hz, 1H), 5.30 (d, J = 17.1 Hz, 1H), 5.24 (d, J = 10.3 Hz, 1H), 4.49 (t, J = 6.9 Hz, 1H),
4.13 (m, 1H), 2.95–2.83 (m, 2H), 2.32 (s, 3H), 1.80–1.68 (m, 1H), 1.66–1.50 (m, 2H),
1.49–1.41 (m, 1H), 1.47 (s, 3H), 1.35 (s, 3H). The spectral data matched those reported
in the literature.63
(Methyl (6′R,7′S)-6-(6′,7′-O-(1′-methylethylidene)-2′-thianon-8′-enyl)-2,4-dihydroxy
benzoate (88)
OMe
OH
HO
O
S
O
O
A solution of thioacetate 81 (195 mg, 0.79 mmol) and resorcylic
bromoester 44 (339 mg, 0.79 mmol) in MeOH (20 mL) was
degassed by sonicating while flushing with argon for 10 minutes.
K2CO3 was then added to the reaction. After 24 h the solvent was
removed in vacuo and the crude product dissolved in EtOAc (20
mL) and sat. NH4Cl (20 mL), the aqueous layer separated and
further extracted with EtOAc (2 x 15 mL). The combined organic layers were then washed
with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo to give a brown
oil, which was purified with flash column chromatography (silica, gradient elution 5:1 to
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3:1 hexanes/EtOAc) to yield the title compound as a clear oil (321 mg, 97%). RF = 0.28
(2:1 hexanes/EtOAc). [α]D21 = +25.7 (c 1.00, CHCl3). 1H NMR (500 MHz, CDCl3) δ
11.68 (s, 1H), 6.33 (d, J = 2.5 Hz, 1H), 6.27 (d, J = 2.5 Hz, 1H), 5.78 (ddd, J = 17.2,
10.3, 7.8 Hz, 1H), 5.30 (ddd, J = 17.1, 1.7, 1.1 Hz, 1H), 5.24 (ddd, J = 10.3, 1.5, 0.9 Hz,
1H), 4.49 (dd, J = 7.7, 6.4 Hz, 1H), 4.09 (ddd, J = 9.1, 6.1, 4.3 Hz, 1H), 3.91 (d, J = 13.6
Hz, 1H), 3.92 (s, 3H), 3.86 (d, J = 13.6 Hz, 1H), 2.42 (t, J = 7.4 Hz, 2H), 1.75–1.65 (m,
1H), 1.64–1.49 (m, 2H), 1.48 (s, 3H), 1.49–1.39 (m, 1H), 1.37 (s, 3H). The spectral data
matched those reported in the literature.63
(Methyl (6′R,7′S)-6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-di-
(methoxymethoxy)benzoate (107)
OMe
MOMO
MOMO
O
S
O
O
NaH (14 mg, 0.35 mmol, 60% dispersion in mineral oil) was
added to a stirred solution of diol 88 (54 mg, 0.14 mmol) in
DMF (1 mL) at 0 ◦C. After 20 min MOMCl (35 µL, 0.42
mmol) were added and the solution allowed to warm to rt.
After 21 h, the reaction was diluted with sat. NH4Cl (10
mL) and extracted with Et2O (10 + 2 x 5 mL). The combined
organic layers were then washed with brine (3 x 5 mL), dried over MgSO4, filtered
and concentrated in vacuo to give a yellow oil, which was purified by flash column
chromatography (silica, gradient elution 10:1 to 5:1 hexanes/EtOAc) to yield the title
compound as a clear oil (54 mg, 81%). RF = 0.30 (2:1 hexanes/EtOAc). [α]D21 = +34.5
(c 1.00, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.73 (d, J = 2.2 Hz, 1H), 6.67 (d, J =
2.2 Hz, 1H), 5.78 (ddd, J = 17.1, 10.3, 7.8 Hz, 1H), 5.28 (ddd, J = 17.1, 1.6, 1.1 Hz, 1H),
5.21 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 5.16 (s, 2H), 5.15 (s, 2H), 4.46 (dd, J = 7.6, 6.4 Hz,
1H), 4.08 (ddd, J = 8.6, 6.1, 4.7 Hz, 1H), 3.88 (s, 3H), 3.70 (s, 2H), 3.47 (s, 3H), 3.46 (s,
3H), 2.48–2.40 (m, 2H), 1.77–1.67 (m, 1H), 1.60–1.43 (m, 3H), 1.46 (s, 3H), 1.34 (s, H).
The spectral data matched those reported in the literature.63
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(Methyl (6′R,7′S)-6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-di-
(methoxymethoxy)benzoic acid (89)
OH
MOMO
MOMO
O
S
O
O
KOH (98 mg, 1.73 mmol) was added to a solution of ester 107
(163 mg, 0.35 mmol) in 2:1 MeOH/H2O (4 mL) and heating at
80 ◦C with stirring. After 2 days the solution was washed with
Et2O, the aqueous layer acidified to pH = 6 with 10 % KHSO3
and the aqueous layer extracted with Et2O. The combined
organic layers were then washed with water 5 mL, dried over
MgSO4, filtered and concentrated to give the crude product as a yellow oil (160 mg).
1H
NMR (500 MHz, CDCl3) δ 6.79 (d, J = 2.2 Hz, 1H), 6.75 (d, J = 2.2 Hz, 1H), 5.81 (ddd,
J = 17.2, 10.2, 7.8 Hz, 1H), 5.30 (ddd, J = 17.1, 1.6, 1.0 Hz, 1H), 5.24 (s, 2H), 5.24 (dd,
J = 10.3, 1.6, 0.8 Hz, 1H), 5.20 (s, 2H), 4.49 (dd, J = 7.6, 6.4 Hz, 1H), 4.14 (ddd, J = 8.4,
6.1, 4.6 Hz, 1H), 3.98 (d, J = 13.4 Hz, 1H), 3.94 (d, J = 13.4 Hz, 1H), 3.52 (s, 3H), 3.49
(s, 3H), 2.50 (t, J = 7.0 Hz, 2H), 1.76 (m, 1H), 1.66–1.50 (m, 3H), 1.49 (s, 3H), 1.36 (s,
3H). The spectral data matched those reported in the literature.63
(4S,6′R,7′S)-Pent-1-en-4-yl 6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-
di(methoxymethoxy)benzoate (90)
O
MOMO
MOMO
O
S
O
O
(R)-4-penten-2-ol (43 µL, 0.42 mmol) was added to a stirred
solution of PPh3 (230 mg, 0.88 mmol) and DIAD (0.18 mL,
0.88 mmol) in THF (6 mL) at 0 ◦C. After 20 min, a solution of
acid 89 (160 mg, 0.35 mmol) in THF (5 mL) was added and
he solution allowed to warm to rt. After 24 h a small potion
of silica was added to the solution and the solvent removed in
vacuo. The dry silica was then loaded on a silica column and gradient eluted with 20:1 to
7:1 hexanes/EtOAc) to yield the title compound as a clear oil (96 mg, 52%). RF = 0.37
(2:1 hexanes/EtOAc). [α]D21 = -3.6 (c 1.00, CHCl3). 1H NMR (500 MHz, CDCl3) δ 6.71
(d, J = 2.2 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 5.85 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 5.78
(ddd, J = 17.9, 10.3, 7.8 Hz, 1H), 5.28 (d, J = 17.1 Hz, 1H), 5.25–5.20 (m, 2H), 5.15 (s,
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2H), 5.14 (m, 2H), 5.13–5.07 (m, 2H), 4.46 (dd, J = 7.3, 6.6 Hz, 1H), 4.09 (ddd, J = 8.5,
6.0, 4.8 Hz, 1H), 3.73 (d, J= 13.7 Hz, 1H), 3.69 (d, J = 13.7 Hz, 1H), 3.46 (s, 3H), 3.45
(s, 3H), 2.51–2.42 (m, 3H), 2.40–2.33 (m, 1H), 1.72 (m, 1H), 1.60–1.40 (m, 3H), 1.46
(s, 3H), 1.34 (s, 3H), 1.34 (d, J = 6.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 166.9,
158.6, 155.8, 139.0, 134.3, 133.8, 118.4, 118.3, 117.7, 110.4, 108.2, 102.3, 94.7, 94.3,
79.7, 77.8, 71.2, 56.2, 56.1, 40.2, 33.8, 31.6, 29.5, 28.2, 25.8, 25.6, 19.4. HRMS (ESI)
calcd. for C27H40O8SNa
+ [M + Na]+ 547.2342, found 547.2339.
(4S,6′R,7′S)-Pent-1-en-4-yl 6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-
di(methoxymethoxy)benzoate 2′,2′-dioxide (108)
O
MOMO
MOMO
O
S
O O
O
O
m-CPBA (75 mg, 0.33 mmol, 77% w/w) was added to a
solution of thioether 90 (77 mg, 0.15 mmol) in CH2Cl2 (4
mL) stirring at 0 ◦C. After 2 h TLC suggested remaining
starting material, excess m-CPBA (38 mg, 0.17 mmol,
77% w/w) was added. After 1 h the reaction was quenched
with 20% Na2SO3 (10 mL), the aqueous layer separated and further extracted with CH2Cl2
(3 x 10 mL). The combined organic layers were then washed with NaHCO3 (10 mL), dried
over MgSO4, filtered and concentrated in vacuo to give a yellow oil, which was purified by
flash column chromatography (silica, 3:1 hexanes/EtOAc) to give the title compound as a
clear oil (50 mg, 61%). [α]D21 = -2.7 (c 1.00, CHCl3). RF = 0.17 (2:1 hexanes/EtOAc).
1H NMR (500 MHz, CDCl3) δ 6.87 (d, J = 2.2 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H), 5.85
(dddd, J = 17.1, 10.1, 7.0, 7.0 Hz, 1H), 5.78 (ddd, J = 17.7, 10.4, 7.9 Hz, 1H), 5.25–5.00
(m, 7H), 5.16 (s, 2H), 4.46 (t, J = 7.0 Hz, 1H), 4.38 (d, J = 14.1 Hz, 1H), 4.28 (d, J = 14.1
Hz, 1H), 4.09 (dd, J = 13.4, 6.1 Hz, 1H), 3.46 (s, 3H), 3.45 (s, 3H), 3.02 (ddd, J = 13.9,
10.3, 5.9 Hz, 1H), 2.94 (ddd, J = 13.9, 10.1, 5.7 Hz, 1H), 2.51–2.44 (m, 1H), 2.42–2.35
(m, 1H), 2.02–1.91 (m, 1H), 1.89–1.80 (m, 1H), 1.52 (tdd, J= 11.2, 7.0, 3.9 Hz, 2H), 1.45
(s, 3H), 1.34 (d, J = 6.3 Hz, 3H), 1.33 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 166.6,
159.0, 156.4, 134.0, 133.7, 128.5, 119.3, 118.6, 117.9, 112.2, 108.4, 104.2, 94.8, 94.3,
79.6, 77.6, 71.7, 56.7, 56.4, 56.3, 51.5, 40.2, 29.3, 28.1, 25.5, 19.5, 18.7. HRMS (ESI)
calcd. for C27H40O10SNa
+ [M + Na]+ 579.2240, found 579.2232
106
(5S,7E,9S,10R)-1,2-(3′,5′-Di-O-methoxymethyl)benzo-4-oxa-14-thia-3-oxo-5-methyl-
9,10-O-(1-methylethylidene) pentadec-7-ene 14,14-dioxide (91)
MOMO
MOMO
O
O
S
O
OO
O
Grubbs’ second generation catalyst (8 mg, 0.009 mmol)
was added to a solution of diene 108 (50 mg, 0.09 mmol)
in CH2Cl2 in a 100 mL MW Teflon
TM reaction vessel.
The vessel was then flushed with argon, sealed and heat
to 75 ◦C over 2 min and held at this temperature for a further 30 min (see Appendix
for a standard microwave temperature profile). After cooling to rt. the reaction mixture
was concentrated in vacuo to give a dark green oil, which was purified by flash column
chromatography (silica, gradient elution, 5:1 to 1:1 hexanes/EtOAc) to give a green oil.
This green oil was then dissolved in CH2Cl2 (6 mL), activated carbon added (10 mg)
and the solution stirred for 30 min to remove remaining Grubbs’ catalyst by-product.
The solution was then filtered through a Celiter plug and evaporated to yield the title
compound as a faint green oil (32 mg, 67%) RF = 0.11 (2:1 hexanes/EtOAc). [α]D21 =
+50.5 (c 1.00, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.98 (d, J = 2.2 Hz, 1H), 6.86
(d, J = 2.2 Hz, 1H), 5.86 (ddd, J = 15.7, 13.2, 6.4 Hz, 1H), 5.68 (dd, J = 15.6, 8.6 Hz,
1H), 5.39 (m, 1H), 5.21–5.16 (m, 4H), 4.52 (dd, J = 8.6, 6.4 Hz, 1H) 4.41 (d, J = 14.4
Hz, 1H), 4.17 (m, 1H), 4.14 (d, J = 14.4 Hz, 1H), 3.47 (s, 3H), 3.46 (s, 3H), 3.08 (ddd,
J = 14.7, 9.8, 4.9 Hz, 1H), 2.95 (m, 1H), 2.86 (m, 1H), 2.44 (dd, J = 15.5, 9.8 Hz, 1H),
1.75 (m, 1H), 1.67 (m, 1H), 1.71–1.56 (m, 2H), 1.43 (s, 3H), 1.40 (d, J = 6.3 Hz, 3H),
1.32 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 167.0 159.3, 156.6, 132.4, 129.0 (2), 118.6,
110.9, 107.9, 103.6, 94.6, 94.4, 76.3, 77.6, 72.3, 56.4, 56.4, 55.4, 51.1, 39.5, 28.3, 27.6,
25.5, 20.8, 18.5. HRMS (ESI) calcd. for C25H36O10SNa
+ [M + Na]+ 551.1927, found
551.1925
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(5′R,6′S,10′S)-2,4-Di-O-(methoxymethyl)-5′,6′-O-(1-methylethylidene) aigialomycin
D (92)
MOMO
MOMO
O
O
O
O
KOH (68 mg, 1.21 mmol) was added to a solution of sulfone
91 (32 mg, 0.06 mmol) in t-BuOH (250 µL) and CH2Cl2 (100
µL). After 2 min, CCl4 (0.24 mL) was added dropwise and
the solution heated to 30 ◦C. After 30 min TLC suggest the
consumption of starting material. The solvent was then removed in vacuo, the crude
mixture dissolved in EtOAc (5 mL) and sat. NH4Cl (5 mL), the layers separated and the
aqueous layer further extracted with EtOAc (2 x 5 mL). The combined organic layers were
then dried over MgSO4, filtered and concentrated in vacuo to give a brown oil, which was
purified by flash column chromatography (silica, 5:1 hexanes/EtOAc) to yield the title
compound as a clear oil (18 mg, 64%) RF = 0.25 (2:1 hexanes/EtOAc). [α]D21 = +4.8 (c
1.00, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.70 (d, J = 2.1 Hz, 1H), 6.68 (d, J = 2.1
Hz, 1H), 6.43 (d, J = 15.6 Hz, 1H), 6.09 (ddd, J = 15.8, 12.7, 6.3 Hz, 1H), 5.86 (ddd, J
= 15.6, 7.8, 2.2 Hz, 1H), 5.67 (dd, J = 15.6, 8.0 Hz, 1H), 5.20–5.12 (m, 4H), 5.16 (m,
1H), 4.57 (dd, J = 7.8, 6.1 Hz, 1H), 4.16 (ddd, J = 10.7, 5.6, 2.3 Hz, 1H), 3.46 (s, 3H),
3.45 (s, 3H), 2.63 (ddd, 10.5, 7.8, 2.9 Hz, 1H), 2.45–2.30 (m, 2H), 2.04 (m, 1H), 1.83
(m, 1H), 1.50 (m, 1H), 1.49 (s, 3H), 1.40 (d, J = 6.3 Hz, 3H), 1.35 (s, 3H). 13C NMR
(125 MHz, CDCl3) δ 167.4, 158.9, 155.1, 136.8, 132.3, 131.9, 129.3, 128.4, 117.9, 108.3,
104.8, 102.5, 94.5, 94.3, 80.1, 77.2, 71.6, 56.2, 56.1, 39.5, 29.0, 28.7, 28.6, 25.8, 21.1.
C25H34O8Na
+ [M + Na]+ 485.2151, found 485.2152.
(5′R,6′S)-Aigialomycin D (69)
OH
HO
O
O
OH
OH
Protected 5′,6′-epi,epi-AmD (17 mg, 0.037 mmol) was stirred
in a solution of in 1:1 v/v MeOH/ 1 M HCl (5 mL). After 2 days
TLC suggest one product. The reaction was then extracted with
EtOAc (10 mL), the combine organic layers washed with brine
(3 mL), dried over MgSO4, filtered and evaporated in vacuo to give a yellow solid, which
was purified by flash column chromatography (silica, 1–5% MeOH/CH2Cl2) to yield the
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title compound plus an unknown isomer (ratio 95:5) as a white solid (11 mg, 90%). RF =
0.45 (9:1 CH2Cl2/MeOH). HRMS (ESI) calcd. for C18H22O623Na
+ [M + Na]+ 357.1314,
found 357.1319. A portion was purified with HPLC for characterisation purposes (C18,
80% MeOH/H2O, Rt = 8.2 min). (9:1 CH2Cl2/MeOH). [α]D21 = + 15.6 (c 0.20, MeOH).
1H NMR (500 MHz, d6-acetone) δ 11.89 (s, 1H), 9.25 (brs, 1H), 7.02 (d, J = 15.4 Hz,
1H), 6.43 (d, J = 2.2 Hz, 1H), 6.28 (d, J = 2.5 Hz, 1H), 6.08 (ddd, J = 15.1, 10.0, 3.4 Hz,
1H), 5.88 (ddd, J = 15.1, 9.2, 4.1 Hz, 1H), 5.67 (ddd, J = 15.1, 9.5, 1.7 Hz, 1H), 5.45 (m,
1H), 4.66 (dd, J = 9.5, 5.9 Hz, 1H), 4.24 (ddd, J = 11.5, 5.9, 2.5 Hz, 1H), 2.67 (ddd, J =
16.2, 9.8, 4.0 Hz, 1H), 2.55 (ddd, J = 15.9, 5.7, 3.2 Hz, 1H), 2.27–2.21 (m, 1H), 2.02–
1.96 (m, 2H), 1.92–1.48 (m, 1H), 1.50 (d, J = 6.6 Hz, 3H). 13C NMR (125 MHz, CDCl3)
δ 172.3, 166.4, 163.3 144.7, 132.9, 131.9, 131.6, 128.6, 108.2, 103.8, 102.5, 80.7, 77.7,
72.1, 72.0, 38.16, 29.0, 18.5.
9.6 Experimental Details for Chapter 5
Pent-4-en-2-yl 2-methyl benzoate (95)
O
O
4-penten-2-ol (90 µ, 0.88 mmol) was added to a solution of 2-
methylbenzoic acid (100 mg, 0.73 mmol) and DMAP (179 mg, 1.47
mmol) in CH2Cl2 (5 mL) stirring at 0
◦C, followed by DCC (168 mg, 0.81 mmol) and
the solution allowed to warm to rt. overnight. The solution was then filtered, the filtrate
quenched with 5% HCl (10 mL) and extracted with CH2Cl2 (2 x 5 mL). The combined
organic layers were then washed with brine (2 x 10 mL), dried over MgSO4, filtered and
concentrated in vacuo to pink liquid, which was purified by flash column chromatography
(silica, 9:1 hexanes/EtOAc) to yield the title compound as a colourless oil (72 mg, 52%).
RF = 0.50 (9:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 7.8 Hz, 1H),
7.39 (t, J = 7.5 Hz, 1H), 7.25 (t, J = 7.1 Hz, 2H), 5.86 (tdd, J = 17.1, 10.0, 7.1 Hz, 1H),
5.23 (sextet, J = 6.3 Hz, 1 H), 5.18 - 5.09 (m, 2H), 2.61 (s, 3H), 2.50 (td, J = 14.0, 6.9
Hz, 1H), 2.43 (td, J = 13.9, 6.8 Hz, 1H), 1.37 (d, J = 6.3 Hz, 3H).
109
EDCI esterification of 2-methylbenzoate
Same procedure as used previously. EDCI (155 mg, 0.81 mmol) and DMAP (179 mg,
1.47 mmol) yielded 95 as a colourless liquid (81 mg, 58%)
EDCI esterification of 2-methylbenzoate
Same procedure as used previously. EDCI (211 mg, 1.10 mmol) and DMAP (269 mg,
2.20 mmol) yielded 95 as a colourless liquid (109 mg, 73%)
EDCI esterification of 2-methylbenzoate
EDCI (211 mg, 1.10 mmol) was added to a stirred solution of 2-methylbenzoic acid (100
mg, 0.73 mmol) and DMAP (269 mg, 2.20 mmol) at 0 ◦C. After 30 min, 4-penten-2-ol (90
µ, 0.88 mmol) was added and the solution left to warm to rt. overnight. The solution was
then quenched with 10% HCl, extracted with CH2Cl2 (2 x 5 mL), the combined organic
layers washed with brine (2 x 10 mL) and concentrated in vacuo to give a pale yellow
liquid, which was purified by flash column chromatography (silica, 9:1 hexanes/EtOAc)
to yield the title compound as a colourless liquid (72 mg, 52%)
HBTU, DMAP and NEt3 esterification of 2-methylbenzoate
HBTU (209 mg, 0.55 mmol) was added to a solution of 2-methylbenzoic acid (50 mg,
0.37 mmol), DMAP ( 135 mg, 1.10 mmol) and NEt3 (155 µL, 1.10 mmol) in CH2Cl2
(4 mL) stirring at 0 ◦C, followed by 4-penten-2-ol (45 µL, 0.44 mmol), and the solution
left to warm to rt. overnight. The reaction was then quenched with NH4Cl (10 mL),
extracted with CH2Cl2 (2 x 10 mL), the combined organic layers was with brine (10 mL),
dried over MgSO4, filtered and concentrated in vacuo to give a yellow liquid, which was
purified with flash column chromatography (silica, 7:1 hexanse/EtOAc) to yield 95 as a
colourless liquid (56 mg, 75%).
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HBTU and DMAP esterification of 2-methylbenzoate
The same procedure as above without NEt3 to yield 95 as a colourless oil (43 mg, 57%).
Attempted HBTU and NEt3 esterification of 2-methylbenzoate
The same procedure as above without DMAP yielded only starting material and traces of
95.
(4R,6′S,7′R)-Pent-1-en-4-yl 6-(6,7-O-(1-methylethylidene)-2-thianon-8-enyl)-2,4-
di(methoxymethoxy)benzoate (66)
O
MOMO
MOMO
O
S
O
O
(S)-4-penten-2-ol (30 µL, 0.28 mmol) was added to a solution
PPh3 (158 mg, 0.60 mmol) and DIAD (120 µL, 0.60 mmol) in
THF (5 mL). After 20 min a solution of acid 45 (110 mg, 0.24
mmol) in THF (5 mL) was added and the solution allowed to
warm to rt. After 16 h, silica gel was added to the reaction and
the solvent evaporated in vacuo. The silica gel was dry loaded
on a silica columned and eluted (gradient elution, 20:1 to 10:1 hexanes/EtOAc) to yield
the title compound as a clear oil (105 mg, 86%). RF = 0.60 (2:1 hexanes/EtOAc). [α]D22
= 30.4 (c 1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.72 (d, J = 2.2 Hz, 1H), 6.69 (d, J
= 1.9 Hz, 1H), 5.85 (dddd, J = 17.2, 10.2, 7.0, 7.0 Hz, 1H), 5.78 (ddd, J = 17.7, 10.4, 7.9
Hz, 1H), 5.25–5.20 (m, 2H), 5.15 (s, 2H), 5.14 (m, 2H), 5.13–5.07 (m, 2H), 4.46 (t, J =
7.0 Hz, 1H), 4.08 (ddd, J = 8.5, 6.0, 4.8 Hz, 1H), 3.72 (d, J = 13.7 Hz, 1H), 3.68 (d, J =
13.7 Hz, 1H), 3.45 (s, 3H), 3.44 (s, 3H), 2.50–2.40 (m, 3H), 2.39–2.32 (m, 1H), 1.71 (m,
1H), 1.60–1.40 (m, 3H), 1.45 (s, 3H), 1.34 (s, 3H), 1.33 (d, J = 6.2 Hz, 3H). 13C NMR
(125 MHz, CDCl3) δ 166.9, 158.5, 155.8, 139.0, 134.3, 133.8, 118.4, 118.3, 117.6, 110.3,
108.1, 102.3, 94.7, 94.3, 79.7, 77.8, 71.1, 56.2, 56.2, 40.2, 33.7, 31.5, 29.5, 28.2, 25.8,
25.6, 19.4. HRMS (ESI) calcd. for C27H40O8SNa
+ [M + Na]+ 547.2342, found 547.2338
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(4R,6′S,7′R)-Pent-1-en-4-yl 6-(6′,7′-O-(1′′-methylethylidene)-2′-thianon-8′-enyl)-2,4-
di(methoxymethoxy)benzoate 2′,2′-dioxide (67)
O
MOMO
MOMO
O
S
O O
O
O
m-CPBA (62 mg, 0.28 mmol, 77% w/w) was added to a
solution of thioether 109 (64 mg, 0.13 mmol) in CH2Cl2
(4 mL) stirring at 0 ◦C and allowed to warm to rt. After
3 h, the solution was quenched with 20% Na2SO3 (5 mL),
separated and the aqueous layer extracted with CH2Cl2 (3
x 5 mL). The combined organic layers were dried with MgSO4, filtered and concentrated
in vacuo to give a colourless oil. The crude product was purified by flash column
chromatography (silica, gradient elution, 3:1 to 1:1 hexanes/EtOAc) to yield the title
compound as a colourless oil (53 mg, 78%). RF = 0.13 (2:1 hexanes/EtOAc). [α]D22
= +54.3 (c 1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.87 (d, J = 2.2 Hz, 1H), 6.85 (d, J
= 2.2 Hz, 1H), 5.85 (dddd, J = 17.1, 10.1, 7.0, 7.0 Hz, 1H), 5.78 (ddd, J = 17.7, 10.4, 7.9
Hz, 1H), 5.25′5.00 (m, 7H), 5.16 (s, 2H), 4.46 (t, J = 7.0 Hz, 1H), 4.38 (d, J = 14.1 Hz,
1H), 4.28 (d, J = 14.1 Hz, 1H), 4.12–4.07 (m, 1H), 3.46 (s, 3H), 3.45 (s, 3H). 3.02 (ddd,
J = 13.9, 10.2, 5.7 Hz, 1H), 2.94 (ddd, J = 13.9, 10.1, 5.7 Hz, 1H), 2.51–2.44 (m, 1H),
2.42–2.35 (m, 1H), 2.02–1.91 (m, 1H), 1.89–1.80 (m, 1H), 1.52 (tdd, J= 11.2, 7.0, 3.9 Hz,
2H), 1.45 (s, 3H), 1.34 (d, J = 6.3 Hz, 3H), 1.33 (s, 3H). 13C NMR (125 MHz, CDCl3) δ
166.6, 159.0, 156.4, 134.0, 133.7, 128.5, 119.3, 118.6, 117.9, 112.2, 108.4, 104.2, 94.8,
94.3, 79.6, 77.6, 71.7, 56.7, 56.4, 56.3, 51.5, 40.2, 29.3, 28.1, 25.5, 19.5, 18.7. HRMS
(ESI) calcd. for C27H40O10SNa
+ [M + Na]+ 579.2240, found 579.2239
(5R,7E,9R,10S)-1,2-(3′,5′-Di-O-methoxymethyl)benzo-4-oxa-14-thia-3-oxo-5-methyl-
9,10-O-(1-methylethylidene) pentadec-7-ene 14,14-dioxide (68)
MOMO
MOMO
O
O
S
O
OO
O
A 100 mL MW TeflonTM reaction vessel was charged
with a solution of Grubbs’ second generation catalyst (8
mg, 0.01 mmol) and diene 67 (50 mg, 0.09 mmol) in
CH2Cl2 (20 mL), flushed with argon and sealed. The
reaction was then heated to 75 ◦C over 2 min and held at this temperature for a further
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28 min (see Appendix for a typical microwave heating profile). After cooling to rt. the
reaction mixture was concentrated in vacuo to give a dark green oil, which was purified
by flash column chromatography twice (silica, 1:1 hexanes/EtOAc) to yield the title
compound as a colourless oil (36 mg, 76%). RF = 0.07 (2:1 hexanes/EtOAc). [α]D18
= - 41.0 (c 1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 6.98 (d, J = 2.2 Hz, 1H), 6.86 (d,
J = 2.2 Hz, 1H), 5.86 (ddd, J = 15.7, 13.2, 6.4 Hz, 1H), 5.68 (dd, J = 15.6, 8.6 Hz, 1H),
5.39 (m, 1H), 5.21–5.16 (m, 4H), 4.52 (dd, J = 8.6, 6.4 Hz, 1H) 4.41 (d, J = 14.4 Hz,
1H), 4.17 (m, 1H), 4.14 (d, J = 14.4 Hz, 1H), 3.47 (s, 3H), 3.46 (s, 3H), 3.08 (ddd, J =
14.7, 9.8, 4.9 Hz, 1H), 2.95 (m, 1H), 2.86 (m, 1H), 2.44 (dd, J = 15.5, 9.8 Hz, 1H), 1.75
(m, 1H), 1.67 (m, 1H), 1.71–1.56 (m, 2H), 1.43 (s, 3H), 1.40 (d, J = 6.3 Hz, 3H), 1.32 (s,
3H). 13C NMR (125 MHz, CDCl3) δ 159.3, 156.6, 132.4, 129.0 (2), 118.6, 110.9, 107.9,
103.6, 94.6, 94.4, 76.3, 77.6, 72.3, 56.4, 56.4, 55.4, 51.1, 39.5, 28.3, 27.6, 25.5, 20.8,
18.5. HRMS (ESI) calcd. for C25H36O10SNa
+ [M + Na]+ 551.1927, found 551.1926
(5′S,6′R,10′S)-2,4-Di-O-(methoxymethyl)-5′,6′-O-(1-methylethylidene) aigialomycin
D (99)
MOMO
MOMO
O
O
O
O
KOH (64 mg, 1.14 mmol) was added to a solution of sulfone
68 (30 mg, 0.06 mmol) in t-BuOH (250 µL) and CH2Cl2 (100
µL) stirring under argon. After 2 min, CCl4 (22 µL) was
added dropwise and the solution heated to 35 ◦C. After 45
min TLC suggest the consumption of starting material. The solvent was then removed in
vacuo. the crude mixture dissolved in EtOAc (5 mL) and sat. NH4Cl (5 mL), the layers
separated and the aqueous layer further extracted with EtOAc (2 x 5 mL). The combined
organic layers were then dried over MgSO4, filtered and concentrated in vacuo to give a
yellow oil, which was purified by flash column chromatography (silica, gradient elution,
9:1 to 4:1 hexanes/EtOAc) to yield the title compound as a clear oil (15 mg, 57%) RF =
0.30 (2:1 hexanes/EtOAc). [α]D24 = -3.9 (c 1, CHCl3). 1H NMR (500 MHz, CDCl3) δ
6.70 (d, J = 2.1 Hz, 1H), 6.68 (d, J = 2.1 Hz, 1H), 6.43 (d, J = 15.6 Hz, 1H), 6.09 (ddd,
J = 15.8, 12.7, 6.3 Hz, 1H), 5.86 (ddd, J = 15.6, 7.8, 2.2 Hz, 1H), 5.67 (dd, J = 15.6,
8.0 Hz, 1H), 5.20–5.12 (m, 4H), 5.16 (m, 1H), 4.57 (dd, J = 7.8, 6.1 Hz, 1H), 4.16 (ddd,
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J = 10.7, 5.6, 2.3 Hz, 1H), 3.46 (s, 3H), 3.45 (s, 3H), 2.63 (ddd, 10.5, 7.8, 2.9 Hz, 1H),
2.45–2.30 (m, 2H), 2.04 (m, 1H), 1.83 (m, 1H), 1.50 (m, 1H), 1.49 (s, 3H), 1.40 (d, J =
6.3 Hz, 3H), 1.35 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 167.4, 158.9, 155.1, 136.8,
132.3, 131.9, 129.3, 128.4, 117.9, 108.3, 104.8, 102.5, 94.5, 94.3, 80.1, 77.2, 71.6, 56.2,
56.1, 39.5, 29.0, 28.7, 28.6, 25.8, 21.1. HRMS (ESI) calcd. for C25H34O8Na
+ [M + Na]+
485.2151, found 485.2151.
9.7 Experimental Details for Chapter 6
All calculations were done using Spartan© ’08, v 1.2.0. For each structure a conforma-
tional search was conducted to determine the equilibrium conformation at ground state
using MMFF, with up to a limit of 70 000 conformers examined. The SCF energy of
the resulting conformation was then calculated using DFT calculations, performed by
employing the B3LYP hybrid Hartree-Fock-density functional method with a 6-31G*
basis set for the ground state structure in a vacuum.
9.8 Experimental Details for Chapter 7
Attempted Simmons-Smith cyclopropanation of alkene 59
CH2I2 (7 µL, 0.08 mmol) was added to a suspension of Zn(Cu) (24 mg, 0.19 mmol) in
Et2O (1 mL) and the mixture sonicated under argon. After 1 h a solution of alkene 59 (20
mg, 0.04 mmol) in Et2O (1 mL) followed by CH2I2 (4 µL, 0.04 mmol). After 10 min the
solution was taken off sonication and left stirring. After 3 h the solution was sonicated
for 1 h then left stirring. After 3 h the solution was quenched with sat. NH4Cl (5 mL)
and extracted with Et2O (3 x 10 mL). The combined organic layers were then dried over
MgSO4, filtered and concentrated in vacuo to give a colourless oil, which was purified by
flash column chromatography (silica, 1:1 hexanes/EtOAc) to yield starting material (18
mg).
114
Attempted Simmons-Smith cyclopropanation of alkene 59 - Furukawa modification
CH2I2 (9 µL, 0.10 mmol) was added dropwise to a solution of Et2Zn (0.43 mL, 0.27
mmol, 0.28 M in CH2Cl2) stirring at −78 ◦C under argon and left to warm to 0 ◦C. After
1 h a solution of alkene 59 (16 mg, 0.03 mmol) in CH2Cl2 (0.40 mL) was added and
the solution allowed to warm to rt over night. The reaction was then quenched with sat.
NH4Cl (2 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were
then washed with brine (2 mL), dried over MgSO4, filtered and concentrated in vacuo
to give a colourless oil, which was purified by flash column chromatography (silica, 1:1
hexanes/EtOAc) to yield starting material (15 mg).
Attempted Simmons-Smith cyclopropanation of AmD (4) - Furukawa modification
CH2I2 (7 µL, 0.08 mmol) was added dropwise to a stirred solution of Et2Zn (0.39 mL,
0.11 mmol, 0.28 M in CH2Cl2) at −78 ◦C under argon and left to warm to 0 ◦C. After 1 h
a solution of alkene 4 (9 mg, 0.03 mmol) in DMF (0.50 mL) was added and the solution
allowed to warm to rt over night. The reaction was then quenched with sat. NH4Cl (2
mL) and extracted with CH2Cl2 (4 x 5 mL). The combined organic layers were then dried
over MgSO4, filtered and concentrated in vacuo to give a yellow oil, which was purified
by flash column chromatography (silica, gradient elution 3–6% MeOH/CH2Cl2) to yield
starting material (8 mg).
Attempted Simmons-Smith cyclopropanation of AmD (4) - Furukawa modification
CH2I2 (10 µL, 0.12 mmol) followed by Et2Zn (0.56 mL, 0.16 mmol, 0.28 M in CH2Cl2)
were added to a stirred solution of alkene 4 (13 mg, 0.03 mmol) in DMF (0.25 mL)
at 0 ◦C under argon and the solution allowed to warm to rt over night. The reaction
was then quenched with sat. NH4Cl (2 mL) and extracted with CH2Cl2 (4 x 5 mL).
The combined organic layers were then washed with brine (2 mL), dried over MgSO4,
filtered and concentrated in vacuo to give a yellow oil, which was purified by flash column
chromatography (silica, gradient elution 3–6% MeOH/CH2Cl2) to yield starting material
(10 mg).
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Attempted oxidation of Amd (4) with DDQ
DDQ (5 mg, 0.02 mmol) was added to a stirred solution of AmD 4 (6 mg, 0.01 mmol) in
dioxane (0.40 mL) under argon. After 22 h the reaction was quenched with sat. Na2S2O3
(1 mL) and extracted with EtOAc ( 3 x 5 mL). The combined organic layers were then
dried over MgSO4, filtered and evaporated in vacuo to give a yellow solid that was purified
by prep. TLC (10% MeOH/CH2Cl2) to yield an unknown oxidation product (2 mg)
Attempted oxidation of Amd (4) with MnO2
MnO2 (187 mg, 2.15 mmol) was sonicated in a solution of AmD [4 (24 mg, 0.07 mmol)]
in dioxane (4 mL) for 20 min under argon, then stirred for 24 h. The solution was then
filtered through Celiter and reduce in vacuo to afford a brown oil (15 mg). 1H NMR
showed a complex mixture of compounds.
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Appendix
Standard temperature profile of the microwave-assisted RCM.
117
1H NMR spectrum of thioether 55 (500 MHz, CDCl3)
118
1H NMR spectrum of epi,epi-AmD 69 (500 MHz, acetone-d6)
119
13C NMR spectrum of epi,epi-AmD 69 (600 MHz, acetone-d6)
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